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ABSTRA.CT
ONE BUG, TWO DRUGS:
A MATHEMATICAL MODEL OF RESISTANCE DYNAMICS
IN THE ICU
Susan L. Calcote White
August 2003
Antibiotic resistance

IS

a problem causing growing concern

In

the medical

community, leading some to speculate that a return to the preantibiotic era is imminent.
The problem of antibiotic resistance is particularly significant in the intensive care unit
(lCU), due to the weakened immune responses of the patients and quantity of antibiotics
administered. One theory proposes that the policy of cycling, or rotating, the antibiotics
used in the ICU may minimize the development of resistance.

Few clinical trials

investigating the effects of cycling have been conducted, and many questions concerning
the impact of cycling policies are unanswered at this point. In this thesis, we develop and
analyze a mathematical model designed to examine resistance dynamics in the ICU in
response to a cycling policy. The uncertainty analysis performed on the model evaluates
the variability of the model outcome due to the uncertainty in estimating input values.
The chosen method of analysis is Latin Hypercube Sampling (LHS). This uncertainty
analysis is extended with the Latin Hypercube Sampling/Partial Rank Correlation
(LHS/PRC) sensitivity analysis technique, which identifies the input variables that have
the greatest effect on the model outcome. The analysis results show that the prediction
imprecision of the model is quite high, leading us to conclude that the model's potential
as an investigative tool cannot be fully realized until input values can be estimated with
greater certainty.
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CHAPTER I
INTRODUCTION

"All the effects of nature are only the mathematical consequences of a small
number of immutable laws. "
Pierre-Simon De Laplace,
Quoted in Men of Mathematics

[1]

The use of mathematical tools to investigate biological phenomena has undergone
rapid growth in recent years, and by all accounts this trend is expected to continue. Ian
Stewart writes in [2], "I predict - and I am by no means alone - that one of the most
exciting growth areas of twenty-first-century science will be biomathematics." (p. xii)
The current flourishing of biomathematics is usually attributed to the introduction of
high-speed computing into the field.

One example illustrating the usefulness of

computers in applying mathematics to biology can be found in the study of animal coat
patterns.

In the 1950s, the great British mathematician Alan Turing suggested that

mathematics could be used to analyze the coat patterns of animals [3]. He believed that
equations could be found which characterize the processes by which coat patterns form.
Over thirty years passed before Turing's idea came to fruition. In the late 1980s, James
Murray, a mathematician at the University of Oxford, wrote a set of equations describing
the aforementioned processes, solved the equations using a computer program, and
transformed the solutions into images with the aid of computer graphics.

Murray's

results have been used to put forward a plausible theory explaining a phenomenon which
has perplexed zoologists for years: why are some animals spotted and others striped?
Today, the fields of biology and mathematics are intersecting in diverse areas to
produce groundbreaking results. Knot theory is used to study DNA, graph theory is used
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to develop phylogenetic trees detailing species evolution, and fractals are used to study
circulatory, respiratory, and nervous systems in the body [4].

Although many

sophisticated mathematical techniques are now available, some biological occurrences
are still best idealized through the use of mathematical models consisting of systems of
differential equations.
Differential equations are particularly appropriate in studying biological processes
which occur with respect to time, such as the growth and decline of a population. The
use of differential equations in population biology dates back over 300 years. In 1798,
Malthus used a simple equation to predict population growth. This equation,
dN =KN

dt

'

where N is population density at time

t

and K is rate of reproduction per unit time, is

sometimes called the Malthus law. Malthus applied this model to human population
growth and deduced that the world's population would grow so large that humankind
would eventually suffer mass starvation [5].

Pierre-Fran<;ois Verhulst, a Belgian

mathematician [6], was an influential figure in the field in the nineteenth century. The
equation

~ =P(P-5P),
where P is the total number of organisms in a population at time t, and

(J

and J are the

birth and death rates, respectively, of the population, is known as the logistic equation, or
Verhulst's equation [7]. The "carrying capacity" in this equation is the ratio

p.
5

In the

twentieth century, Alfred J. Lotka and Vito Volterra, who arrived at their results
independently of each other, played significant roles in population biology.

The

equations which make up the classic deterministic model of a single predator-single prey
system are called the Lotka- Volterra equations. These equations are
dH
-=H(a-aP)
dt
dP
-=P(-b+PH)
dt
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where Hand P are the populations of predator and prey, respectively, at time t, and a is
birth rate of prey, b is death rate of predator, and a, B are parameters relating to species
interaction [8].

This model has been extended for use in a system with multiple

predators and prey.
Historically, even models which are somewhat inaccurate in representing realworld phenomena have proven to be useful in other ways.

For example, in 1935,

entomologist A.J. Nicholson and physicist V.A. Bailey proposed a model predicting the
oscillations in the populations of two species which form a host-parasitoid pair [5,6]. The
Nicholson-Bailey model, a system of two difference equations, is less stable than most
host-parasitoid systems which occur in nature. However, by placing limitations on the
model (for example, taking into account the fact that population growth is finite), the
model becomes more stable. In this way, the model has been used to explore situations
which have a stabilizing influence on host-parasitoid populations [5].
The model credited to Lotka and Volterra, shown above, has also been the target
of criticism; it is often characterized as a naIve oversimplification of reality. The LotkaVolterra equations, for instance, do not take into account the age distribution of the
population or the amount of resources available. But the fact that the model has been
influential in biomathematics cannot be disputed. Volterra, in particular, was aware that
the model was a simple one. He brought to the field of population biology his training in
classical mechanics. His method was to begin with a few very simple hypotheses, find a
mathematical representation of the problem, and gradually refine the model over time to
approximate nature more closely [6].
Since the early twentieth century, population biology models have been used in
the study of infectious diseases, both microparasitic (caused by viruses and bacteria) and
macroparasitic (caused by larger organisms, such as worms). In 1911, Sir Ronald Ross
used a mathematical model detailing the relation between mosquitoes, humans, and
malaria to bolster his argument that controlling mosquito populations was the best way to
curb the incidence of malaria [6]. Kermack and MacKendrick were also pioneers in this
area. They proposed an early epidemic model [5] consisting of three ordinary differential
equations:
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dS = -PIS
dt
dI
dt

- = PIS-vI

dR
dt

= vI.

In this model, the population is divided into three sUbpopulations: those susceptible to the
disease (S), those infected by the disease (1), and those "removed," which are no longer
able to contract the disease (R). The rate of disease transmission is denoted by 8 and the
rate of removal is v. The interpretation of the meaning of v varies depending on the
definition of R. For example, if population members are classified as "removed" because
they have gained resistance to the disease, then v is the rate at which resistance is gained;
if population members enter class R by death, then v is death rate due to disease.
Kermack and Mac Kendrick showed that this model was a close fit for data obtained from
a 1906 plague which afflicted residents of Bombay. Kermack and MacKendrick are also
credited with discovering the "threshold effect," the idea that a disease cannot become
endemic unless the host population size is large enough.
Today, mathematical models consisting of differential equations are used to
explore a variety of situations of interest to the medical community. Epidemic models
are still in use; for example, models have been used to assess the consequences of
intravenous drug use as it relates to the HIV transmission rate [9] and to predict the effect
of vaccination policies on the public [5]. Models can also be used to study the effects of
patient therapy; for example, the distribution of drugs throughout the body or glucoseinsulin dynamics in a diabetic patient can be accurately modeled. With the advent of
high-speed computing, increasingly complex models are being formulated and
numerically solved. This scenario offers unprecedented opportunity to the clinician in
gathering information which could lead to improvements in patient care. In past years,
health-care workers have made decisions based primarily on data obtained from clinical
studies or empirical observations. However, the medical establishment is often reluctant
to carry out experiments which may not meet ethical standards, or may be too costly
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and/or time-consuming. Hence, this data is not always readily available.

If a model with

good predictive ability can be constructed to investigate the dynamics of a medical
problem, the solution of the model can be studied and the results can take the place of
experimental data. The model is thus able to produce information that cannot be obtained
by other means.
One serious problem facing the medical community today is the development of
antibiotic resistance by pathogenic (disease-causing) bacteria. Certain patient groups are
at increased risk for infection by resistant bacteria.

ICU patients make up one

particularly vulnerable group. These patients often have weakened immune systems due
to underlying illness, coupled with natural barrier defenses being compromised through
the use of invasive medical devices (IV's, catheters, surgical wounds, etc.). In some
cases, it is impossible to treat patients infected with resistant bacteria, leading to an
increased mortality rate.
The dilemma facing the medical community is that resistance develops primarily
as a result of antibiotic use. The antibiotics provide the selective pressure allowing
bacteria with resistance-conferring mutations to flourish, i.e., " ... antibiotics sow the seed
of their own potential downfalL." (Levy, [10], p.vii) The clinician is essentially caught
in a catch-22: antibiotic treatment is ineffectual for those patients most in need of it, such
as patients in the ICU.

It has been postulated that resistance may be minimized by

carefully controlled antibiotic policies. One theory proposes that a policy of "cycling," or
rotating, the antibiotics used in the ICU may minimize resistance development by
keeping the bacteria "confused." In other words, the mechanisms of resistance vary
depending on the drug in use, so if the selective pressure allowing for the development of
resistance is constantly changing, the bacteria cannot become resistant.

Before the

bacteria have a chance to develop resistance to a particular drug, the drug is removed
from the environment and replaced with a different one.
The strategy of cycling seems promising in theory, but many questions are
unanswered at this point.

Is cycling effective in preventing resistance?

If so, is it

effective for all species of pathogenic bacteria? What is the optimal cycle length to
prevent resistance? What combination of drugs should be cycled? What are the longterm effects of cycling? Clearly it is implausible to conduct clinical trials investigating so

5

many different scenarIOs.

Mathematical modeling is proving to be indispensable in

exploring the effects of ICU cycling policies. If a model which examines the dynamics
of resistance in the ICU can be constructed and its predictive ability is good, such
questions can be easily answered by perfonning model simulations.
The output of a mathematical model of resistance dynamics must be matched with
experimental data before it can be used to answer questions such as those listed above.
Several hospitals have conducted clinical trials investigating the effects of cycling. One
of these trials was recently perfonned at Hennepin County Medical Center (HCMC) in
Minneapolis, MN. The antibiotics ciprofloxacin and piperacillinitazobactam were rotated
every four months in the ICU at HCMC.

Many bacterial species, including

Staphylococcus aureus and Pseudomonas aeruginosa, were collected from infected
patients and tested for resistance throughout the study. The duration of the trial was 16
months (480 days), and the data set from the trial was collected in September 2001 by Dr.
Dean Tsukayama, infectious disease specialist at HCMC. The data from this experiment
will be discussed in Chapter 5 of this paper. Another clinical trial is currently being
perfonned at Utrecht University Medical Center in Amsterdam; the results from this trial
are not yet available.
The purpose of this thesis is to construct and evaluate a mathematical model that
may be used to investigate the dynamics of resistance development in the ICU in
response to a cycling policy. The model we present is a system of differential equations
containing some of the elements of the influential population biology models presented
earlier in this chapter, such as logistic growth (Verhulst) and the division of a population
into subpopulations, where population members may move from one subpopulation to
another (Kennack and MacKendrick). The model is designed to track the gain and loss
of antibiotic resistance in a bacterial population when two drugs are cycled. The bacterial
species chosen for the model in this paper is Pseudomonas aeruginosa and the drugs are
ciprofloxacin and piperacillinitazobactam; these choices were made so that the model
could ultimately be compared with the data from the clinical trial perfonned at HCMC.
To accomplish the task, we merge biological principles, mathematical modeling,
and computing capabilities. Chapter 2 deals primarily with the biology of the situation,
with

research

into

the

properties
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of

P.

aeruginosa,

ciprofloxacin,

and

piperacillinltazobactam, and the unique challenges faced by health-care workers fighting
bacterial infection in the ICU.

Chapter 3 focuses on the mathematical modeling

processes used to develop the model. The "chemostat" model is introduced in Chapter 3.
A discussion of the equations used in the chemostat model is included, as well as the
biological justifications for using this particular model as a basis for the model developed
in this paper. We bring our computing capabilities to bear in Chapters 4 and 5. Chapter
4 describes the chosen method of analysis used on the model, Latin Hypercube Sampling,
and presents the results of that analysis. In Chapter 5, we present a model simulation
obtained through the use of a computer program and discuss the implications of the
results found in Chapter 4. We also discuss the difficulties encountered in matching the
model output to experimental data, and conclude with a discussion of the directions this
work may take in the future.
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CHAPTER II

Pseudomonas Aeruginosa
"It, as with the wolf-like carnivore, is a pathogen characterized by hemorrhage
and necrosis, yet like the cowardly part of the hyena, Pseudomonas frequently colonizes
the human host, waiting for an opportunity to spring. "
Robert B. Fick, Jr.,
Pseudomonas aeruginosa the Opportunist: Pathogenesis and Disease

[11 ]

2.1 The Microbial Hyena
The first published scientific study of Pseudomonas aeruginosa appeared over
120 years ago. A physician in France, Dr. Chauvel of Val-de-Gnlce, noticed that the
bandages used on some of his patients had an unusual blue-green stain. He gave the used
bandages to Carle Gessard, a French pharmacist, who began tests to determine the cause.
Gessard identified the pigment as pyocyanine; "pyo" is a prefix meaning pus, and
"cyanine" is a type of blue dye. The pyocyanine was being emitted by an organism that
Gessard described as colorless, globular, aerobic, and very mobile. Gessard published his
results in an article entitled "On the blue and green coloration of bandages" in 1882
[12,13]. Gessard's paper dealt almost exclusively with the chemical properties of the
pigment-producing organism that is known today as Pseudomonas aeruginosa. In the
years since its discovery, P. aeruginosa has gone by several different names: Bacillus
pyocyaneus,

Pseudomonas polyeolor,

Bakterium aeruginosa,

and Pseudomonas

pyoeyaneus (note that several of these names indicate the presence of the pyocyanine

discussed by Gessard).
Pseudomonas aeruginosa

IS

a bacterial species.

Bacteria are microscopic

unicellular organisms which reproduce by cell division. Bacteria are present both in the
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natural world and in living beings. The average human being, for example, is host to
approximately 10 14 bacteria in the form of intestinal and skin flora [10]. Clearly, then, it
is not the case that all bacteria cause disease. However, some bacteria, when present in
the body as a sufficiently large colony, are disease-causing. These bacteria are called
pathogenic.
Bacteria are classified into two groups: Gram-positive and Gram-negative. This
classification is made according to whether a bacterium retains a violet stain used during
a procedure called Gram's method. Gram's method is named for the Danish physician
Hans Christian Gram (1853-1938). In the latter part of the 19th century, Gram created a
technique whereby he first stained a bacterial specimen with a deep purple dye and then
washed it. Those specimens which retained the color after washing were classified as
Gram-positive (or stain-positive); those which did not were Gram-negative.

P.

aeruginosa falls into the second category. A list of several common pathogenic bacteria

is shown in Table 1.
Table 1 Common Pathogenic Bacteria

Gram-positive

Gram-negative

Streptococcus pneumoniae

Escherichia coli

Staphylococcus aureus

Hemophilus injluenzae
Neisseria gonorrhoeae
Pseudomonas aeruginosa

The Gram-positive/Gram-negative classification is significant in that it gIves
important information about the cell wall of a bacterium. The Gram-positive bacteria
have a single cell wall, while the Gram-negative bacteria have a cell wall consisting of
three layers. The dye used in Gram's method is thus able to penetrate the outer layer of a
Gram-positive specimen. This distinction between Gram-positive and Gram-negative
bacteria must be taken into account when studying the effectiveness of antibiotics against
different types of pathogenic bacteria; this will be discussed in more detail in Section 2.2.
The P. aeruginosa species is a member of the family Pseudomonadaceae. This
family of rod-shaped, Gram-negative bacteria, called pseudomonads, is a large group
containing a variety of species. The pseudomonads have been known to grow in both
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aerobic and anaerobic conditions, and are found in such diverse environments as water,
soil, decaying matter, sewage, insects, plants, and animals. Four species of this family
are known to be pathogenic to humans throughout the world; they are P. aeruginosa, P.
mallei, P. cepacia, and P. pseudomallei. Only P. aeruginosa and P. cepacia are present

in significant numbers in the United States [11]. Certain species of pseudomonads, P.
aeruginosa in particular, have plasmids which allow for the development of special

features such as antibiotic resistance [14]. Plasmids are units of DNA within a cell that
are independent of the chromosomal DNA and can transfer genetic material from cell to
cell.

Plasmids directly contribute to the ability of bacteria to survive within their

environment by facilitating the evolution of the bacteria, the end result being that the
bacteria are better able to deal with harmful substances within that environment.
Prior to 1947, P. aeruginosa was not considered a serious threat by the medical
community, with only 91 cases of human infection described in the literature. However,
the second half of the century saw a sharp increase in the number of cases of
Pseudomonas infections, accompanied by a rising mortality rate.

What could have

caused such a change? Pseudomonas aeruginosa is often described as an "opportunistic"
pathogen [11,15] because Pseudomonas infections occur almost exclusively in the
immunocompromised host. With the health care advances of the mid to late twentieth
century, the life expectancies of these patient groups began to increase, thereby
increasing the numbers of those most vulnerable to Pseudomonas infections.
Although Pseudomonas poses no threat to the healthy host, those at risk face the
possibility of quite serious complications. P. aeruginosa, as befits a pathogen known as
opportunistic, can "infect virtually any part of the body, causing endocarditis, respiratory
infections, bacteremia, central nervous system infections, ear and eye infections, bone
and joint infections, and infections of the urinary tract, soft tissues and skin, and
gastrointestinal tract" [15] (p. 297).

Because P. aeruginosa preys exclusively on the

weak and vulnerable among us, it has been called a "microbial hyena" [11].
Certain hospital patient groups are particularly vulnerable to Pseudomonas
infections. One such group is cystic fibrosis patients. Cystic fibrosis (CF) is the most
common lethal genetic disease among Caucasians [11,15], and those suffering from CF
often deal with chronic respiratory infections caused by P. aeruginosa. In these patients,
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antibiotic treatment fails to eradicate the infection due to the development of antibiotic
resistance. The eventual result is impaired lung function and an increased mortality rate.
The European Epidemiologic Registry of Cystic Fibrosis reported in 2001 that 54.2% of
children with CF between the ages of 6 and 12 and 78.8% of adults with CF over the age
of 18 were afflicted with Pseudomonas infections [16].
P. aeruginosa infection is the leading cause of death among bum patients, with

mortality rates approaching 77% [15]. In fact, bum patients were among the first patient
groups in which the severity of the pathogenicity of Pseudomonas aeruginosa was
recognized and studied.

The burned mouse model was developed in 1975 for this

purpose, and today it remains a well-known model used to study Pseudomonas infections
in bum patients.
A third group likely to suffer from P. aeruginosa infection are those critical care
patients in the

leu.

While a healthy patient is protected by mucosal and skin barriers

which present an impediment to bacteria attempting to enter the body, those barriers are
often breached in an ICU patient through the use of invasive devices such as ventilators,
catheters,

and

intravenous

immunocompromised

III

drugs

[17].

In

addition,

the

ICU

patient

is

many cases, due to malnutrition and/or serious underlying

illness.

2.2 Antibiotic Treatment and Resistance

The first line of defense against bacterial infection is antimicrobial therapy, i.e.,
the use of antibiotics, but antimicrobial-resistant pathogens are becoming increasingly
common today. The problem of resistance was recognized even during the early days of
antibiotic use. Alexander Fleming, the bacteriologist who discovered penicillin in 1928,
was able to produce mutant bacteria in the laboratory that could not be killed by
penicillin.

He cautioned the medical community against the misuse of antibiotics,

warning that such misuse would result in resistant strains of bacteria [10]. His words
have proven prophetic with the passage of time. Today, the problem of resistant bacteria
has reached such proportions that the journal Archives of Internal Medicine recently
published an article with the startling subtitle "The preantibiotic era has returned" [18].
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Antibiotics are substances produced by microorganisms (as opposed to being
man-made) which are able to kill or inhibit the growth of bacteria. When antibiotics first
came into use, they were considered nothing short of miraculous. Here at last was a
"magic bullet" which was able to target and eradicate pathogenic bacteria. However, at
present, even bacteria which have been susceptible to every known antimicrobial agent
for years are developing resistance [10,19]. The evolutionary law of survival of the fittest
applies to the microscopic world as well as the macroscopic; with the widespread use of
antibiotics, the resistant bacteria are rapidly gaining an evolutionary advantage over the
suscepti bIe.
The origins of antibiotic resistance are varied (see Table 2). One way in which a
strain of bacteria may become resistant is through genetic mutation in the chromosome of
the bacteria. In some cases a single mutation causes resistance to arise; in other cases a
less likely sequence of mutations must occur.
Table 2 Origins of Resistance

Spontaneous genetic mutation
Gene exchange by plasmids
Latent resistance
Emergence of resistant subpopulations
Another way in which a bacterial strain may become resistant is through the
exchange of genetic material. Plasmids, those non-chromosomal pieces of DNA briefly
discussed in Section 2.1, playa vital role here. Plasmids are able to lose old genes or
acquire new ones, and these genes sometimes code for antibiotic resistance. Plasmids
can transfer not only from one bacterium to another within a colony, but also from one
bacterial species to another. There are even reported cases of the transfer of genetic
information between Gram-negative and Gram-positive bacteria [19]. A third way in
which resistance may occur is known as latent resistance. Here, the chromosome of an
organism contains inactive genes which confer resistance once they become active. The
inactive genes are more likely to become active in the presence of antibiotic. Finally,
some bacterial species contain a small resistant subpopulation, which becomes dominant
once an antibiotic has killed the susceptible portion of the population. No matter the
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method by which bacteria acquire a defense mechanism, once acquired the bacteria may
become resistant to an entire class of antibiotics, rather than just a single drug.
Furthermore, in each of the methods described, it is the use of antibiotics which provides
selective pressure favoring the development of resistance [10,19,20].
The treatment of P. aeruginosa infection is a notoriously difficult task for the
clinician. Mortality rates from such infections are high, sometimes exceeding 40%, and

P. aeruginosa has demonstrated an ability to rapidly acquire resistance [15,21].
Giamarellou and Antoniadou assert in [21] that" ... steadily increasing resistance rates are
reported worldwide, rendering the end of antibiotics for P. aeruginosa an approaching
reality." (emphasis in original) The choice of antibiotic for any particular patient is
dependent on several factors, including the site of infection in the body.

Since P.

aeruginosa is able to infect so many different areas of the body, it is imperative that
physicians have a diverse group of antipseudomonal antibiotics from which to choose. In
fact, several different classes of antibiotics have achieved some measure of success in
fighting P.

aeruginosa, including p-lactams, aminoglycosides, polymyxins, and

quinolones [15,22]. We restrict our focus in this paper to two of these: the p-lactams and
the quinolones. The mechanisms of resistance displayed by P. aeruginosa in response to
these two classes of antibiotics are shown in Table 3.

Table 3 Mechanisms of Resistance
p-lactams

Gram-negative outer membrane
Production of p-lactamase
Alteration of penicillin-binding proteins

Quinolones Gram-negative outer membrane
Efflux
Alteration of DNA gyrase

An antibiotic must reach its target to be effective, and this target site varies from
one antibiotic to another, as does the mechanism of resistance the bacteria develop to
attempt to inactivate the antibiotic. The p-lactam antibiotics, in general, must reach the
cell wall to be successful in killing or inhibiting the growth of the bacterium. Here P.

aeruginosa, as a type of Gram-negative bacteria, has an edge over the Gram-positive

13

bacteria in one particular mechanism of resistance. The drug must pass through an outer
membrane that is present only in Gram-negative bacteria. The ability of the drug to cross
the membrane is further compromised by mutations which may occur in the bacteria,

Pis the production of p-Iactamase by the bacteria. Pinactivates the p-Iactam. To address the problem of P-

making this membrane even less permeable. Another mechanism of resistance to
lactams which has developed
lactamase is an enzyme which

lactamase production, clinicians often combine a p-Iactam antibiotic with a p-Iactamase
inhibitor during the course of therapy [23]. The p-Iactamase inhibitor, while itself not
bactericidal, does prevent the p-Iactamase from rendering the p-Iactam ineffective. For
example, the antibiotic piperacillin, a penicillin derivative, is often combined with the

P-

lactamase inhibitor tazobactam, with generally good results [22,24,25,26]. However, as
one might expect, some p-Iactamases are becoming resistant to p-Iactamase inhibitors. A
third way in which P. aeruginosa may gain resistance to a p-Iactam antibiotic is by
altering the penicillin-binding proteins (PBP's) on its surface. As a result of this change,
the drug is no longer able to bind to its target.
Quinolones primarily target DNA gyrase

III

Gram-negative bacteria [27],

interfering with the ability of the bacteria to reproduce by inhibiting the replication of its
DNA.

This mechanism of action is peculiar to the quinolones among all antibiotic

classes [28]. The fluoroquinolones are a relatively new class of quinolones which are
particularly

effective

against

Gram-negative

bacteria

[29].

Ciprofloxacin,

a

fluoroquinolone, is the most powerful qui no lone against P. aeruginosa [15,21,28]. Since
the quinolones target a different site than the p-Iactams, predictably, the mechanisms of
resistance are different as well, with one exception. The mechanism of resistance that is
common to both p-Iactams and quinolones is the Gram-negative outer membrane. Once
again, the drug must cross this membrane and mutations in the bacteria may make that
difficult. A second mechanism of resistance that P. aeruginosa may develop against the
quinolones is called efflux. In this case, the efflux mechanism, which is positioned in the
cytoplasmic membrane, pumps the drug out of the cytoplasm before it can complete its
task. Finally, P. aeruginosa may become resistant by altering its DNA gyrase, the target
of the quinolones. The result is the same as with the p-Iactams and the altered PBP's; the
quinolone is not able to bind to its target.
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Although this section has focused primarily on one type of bacteria and two
antibiotic classes, the problem of resistance is widespread, leading to international
concern. This is not just the problem of individual hospitals, but a serious public health
issue [18,30]. Unfortunately, treatment and resistance go hand-in-hand; the "antibiotic
paradox" described by Levy in [10] is that resistance to antibiotics is actually a product of
treatment with antibiotics.

So it is that we look to our treatment policies to minimize

resistance. Some strategies are well-known and undisputedly effective, such as ensuring
that the patient completes the full course of antibiotic treatment and that the clinician
prescribes antibiotics only when medically necessary. In addition, many recognize the
need for well-defined antibiotic policies which govern the patterns of antibiotic use [31],
but it is unclear exactly which of these strategies will work [32].
2.3 Fighting Infection in the leu
With the exception of some CF patients, most of those fighting Pseudomonas
infections acquired the infection while in the hospital.

These hospital-acquired, or

nosocomial, infections, occur frequently with P. aeruginosa because this bacterial species
preys almost exclusively on the immunocompromised host, a population which is likely
to be hospitalized. Hospital-wide, P. aeruginosa is the second most common Gramnegative nosocomial pathogen; only E. coli (Gram-negative) and S. aureus (Grampositive) occur more frequently [15]. Nosocomial infections due to resistant bacteria are
particularly damaging to both hospitals and patients.

A recent study found that a

confirmed hospital-acquired infection imposes on the hospital an increased cost of
$15,275 per patient [33]. If the patient is infected with resistant bacteria, his/her hospital
stay will likely be longer and thus more costly to the hospital; the hospital stay of such a
patient is approximately 20 days longer than the stay of a similar patient infected with
susceptible bacteria [34].
The ICU is a clinical unit which faces a particularly daunting task in fighting any
type of bacterial infection. Here resistance rates are known to be higher than in any other
area of the hospital [19,21], and antimicrobial-resistant pathogens may enter the ICU
environment by several pathways unique to the ICU. Critical care patients sometimes
require immediate treatment, so that health care workers are not able to properly disinfect
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their hands before administering treatment. This may result in antimicrobial-resistant
pathogens crossing from patient to patient or being carried into the ICU from the outside
environment. Critically ill patients are often transferred from one hospital to another, and
some patients unknowingly carry resistant bacteria acquired from the faCility from which
they are transferred [17]. While antimicrobial-resistant pathogens are more likely to be
present in the ICU, a typical ICU patient is more likely to become infected with such
pathogens during his/her stay in the ICU than a patient in another area of the hospital. In
addition to the immunocompromised status and weakened natural defenses of ICU
patients discussed in Section 2.1, these patients are more likely to have previous exposure
to antibiotics, which is perhaps the single greatest factor predisposing a patient to
antibiotic resistance.
Not surprisingly, then, P. aeruginosa is one of the significant pathogens in the
ICU [18,35], where the compromised immune systems of the patients and ease with
which P. aeruginosa develops resistance combine to make P. aeruginosa infection a
formidable enemy.

Recently released data from the National Nosocomial Infections

Surveillance (NNIS) System shows that P. aeruginosa isolates collected in the ICU
display resistance to five commonly used antibiotics, with resistance rates ranging from
13.9% to 37.8%, depending on the antibiotic [36]. Resistance rates are sometimes much
higher in a single hospital or particular geographic region [17,35,37].

The types of

infection caused by P. aeruginosa in the ICU are usually either ventilator-associated
pneumonia or catheter-associated urinary tract infections [17]. Although pneumonia may
be caused by bacteria other than P. aeruginosa, those with this singular type of
pneumonia are more likely to suffer from multiple organ failure and death [37].
Mortality rates can exceed 50% [21].
Many strategies have been proposed to fight nosocomial infection in the ICU.
Some strategies do not involve a change in antibiotic policy, such as stricter adherence to
guidelines concerning hand-washing and the use of gloves, gowns, and face masks by
health care workers, as well as minimizing the number of hospital personnel which move
in and out of the ICU [17]. Another strategy proposes the isolation of patients infected
with resistant bacteria [19]. While these strategies are likely to reduce the frequency of
nosocomial infection, the use of antibiotics will remain a necessity in many cases.
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However, there are no antimicrobials in use today that have not met with resistance [20].
We cannot depend on the discovery of new antibiotics to overcome the problem of
resistance, as a tremendous amount of time (almost 20 years [23]) and money ($100 to
$350 million [20]) are required to bring a new drug from discovery to market in the
United States.
Thus the medical community searches for a policy governing antibiotic use which
will maximize the effectiveness of the antibiotics in use today, while minimizing the
development of resistance in bacteria. Lepper, et al. [38] and Lesch, et al. [39] have
presented data suggesting that when a hospital has an antibiotic control policy in place,
resistance rates are reduced. However, Lesch argues that it is crucial that the ICU be
studied separately from other units of the hospital; else unit-specific trends in
antimicrobial use and resistance may not be recognized. In a study performed by the
Centers for Disease Control and Prevention (CDC), the authors conclude that in
monitoring antibiotic resistance in hospitals, antibiotic use and resistance must be
observed jointly [40]. In both [39] and [40], the authors argue that a complex model is
necessary to confirm a correlation between use and resistance of antibiotics.
In the ICU, it is often necessary to begin antibiotic treatment immediately,
without waiting for laboratory results [41]. This type of therapy is known as empiric
therapy, and the antibiotic used in such a situation is informally referred to as the "go-to"
antibiotic in the ICU. The go-to antibiotic must have a broad spectrum of activity; i.e., it
must be active against a wide variety of pathogenic bacteria. It has been suggested that if
several go-to antibiotics are routinely rotated, the development of resistance will be
minimized because the selective pressure favoring certain types of resistance will be
periodically removed when another antibiotic is put into place. This policy is known as
"cycling" antibiotics [42]. For example, if two antibiotics from different classes are
routinely rotated (say, a p-lactam and a quinolone), then, theoretically, the mechanisms of
resistance developed by the bacteria to fight the p-Iactam will leave it susceptible to the
quinolone, and vice versa. Essentially, the bacteria are "confused" and as soon as they
begin to develop a mechanism of resistance, that mechanism becomes useless. Note that
we make the assumption that in the absence of a specific antibiotic, the bacteria
susceptible to that antibiotic will out-compete the bacteria resistant to the antibiotic. This
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is because resistance to antibiotics imposes a fitness cost on bacteria [43], so we may
assume that in the absence of an antibiotic, the susceptible, or "wild-type," bacteria will
dominate the bacterial population.
Raymond, et aI., in [44], present the results of a study comparing two years in an
ICU at the University of Virginia Health Sciences Center. During the first year, no
antibiotic control policy was in place, but during the second year, empirical antibiotics
were rotated quarterly. They found that mortality rates decreased, as did the number of
antimicrobial-resistant infections, although the average length of hospital stay did not
change.

The authors conclude that the results seem promising, and further study is

necessary.
The policy of cycling antibiotics has its critics, as well. Bonhoeffer, Lipsitch, and
Levin [31] argue that it is always preferable to treat equal proportions of infected patients
with different drugs simultaneously (in the case of two drugs, they call this 50-50
treatment) rather than cycling each drug on and off. The ideal time period for cycling
drugs is one which selects the antibiotic with the smallest amount of resistance in the
patient population at a given time.

But the point in time at which the amount of

resistance is at a minimum is when the drug is first cycled into use.

So, theoretically,

the best cycling policy is one which switches back and forth between the drugs with each
new patient, which is identical to 50-50 treatment. It should be noted that this argument
is based on the results of a mathematical model, rather than experimental data, and is not
specific to the leu.
While it remains unclear whether cycling antibiotics is the solution, it is certain
that further study is necessary. Several guidelines for this study have been presented in
this section; specifically, (1) the

leu should be studied separately from other areas in the

hospital, (2) antimicrobial use and resistance should be jointly observed, and (3) a
mathematical model is necessary to confirm a correlation between use and resistance of
antibiotics when examining an antibiotic control policy. In the following chapter, we
present a mathematical model which meets these three specifications; it is designed to
examine the dynamics of a bacterial population in the

l
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leu

when two antibiotics are

CHAPTER III
THE ONE BUG-TWO DRUG MODEL

" ... it is the view in this work that studying the chemostat is much like studying the

pendulum in physics; the precise assumptions for the pendulum model are not met, but
there is much to be learned about oscillations by studying it. "
Hal Smith & Paul Waltman,
The Theory of the Chemostat: Dynamics of Microbial Competition
[45]

In this chapter, we present a mathematical model, based on the chemostat,
which was designed to assess the dynamics of bacterial population in an ICU which has
implemented a cycling policy that switches back and forth between two antibiotics as the
empiric therapy drug of choice. The model consists of six ordinary differential equations
which track the number of bacteria in the subpopulations that are (i) susceptible to both
drugs, (ii) resistant to drug 1 and susceptible to drug 2, (iii) susceptible to drug 1 and
resistant to drug 2, and (iv) resistant to both drugs, as well as (v) amount of drug 1 in the
ICU, and (vi) amount of drug 2 in the ICU, at any given time. Since the model examines
one particular type of bacteria displaying various degrees of resistance to two antibiotics,
we call it the "one bug-two drug" model. For the purposes of the model analysis in
Chapter IV and comparison with experimental data (see Chapter V), the "bug" is
assumed

to

be

P.

aeruginosa,

drug

1

is

ciprofloxacin,

and

drug

2

IS

piperacillinltazobactam. However, the model can be easily adapted to other bacteria and
antibiotics by changing the parameter values.
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3.1 The Chemostat Model

The chemostat is a simple piece of laboratory equipment which plays an
important role in the study of the growth of microorganisms. Many ecological models
are based on the chemostat; for instance, the chemostat has been used to model
wastewater treatment problems [45]. The chemostat has gained widespread acceptance
as a useful model in ecology [46,47]. F.M. Williams writes in [48] that the "chemostat is
the best laboratory idealization of nature for population studies. It is a dynamic system
with continuous material inputs and outputs, thus modeling the open system character
and temporal continuity of nature." (p. 200)
The chemostat, as described by Smith and Waltman in [45], consists of three
connected devices.

The first container is called the feed bottle. It holds a solution

containing all of the nutrients which are necessary for the growth of the microorganism.
The second container is the bacterial growth chamber, or culture vessel.

The third

container is the overflow vessel. The nutrient solution is pumped out of the feed bottle
and into the culture vessel at some fixed rate. At the same time, the culture vessel has an
outflow valve which allows its contents to flow out of the culture vessel and into the
collection vessel at the same rate. Since inflow and outflow are always equal, the volume
of the culture vessel is constant.

The culture vessel contains both nutrient and

microorganisms, so some microorganisms, as well as a small amount of nutrient, will be
removed from the culture vessel during outflow. It is assumed that the culture vessel is
kept well stirred, and all parameters affecting the growth of the microorganisms (e.g.,
temperature, pH level) are fixed.

With these assumptions in place, bacterial growth

depends only on the amount of nutrient in the culture vessel at any given time.
Smith and Waltman give two ordinary differential equations to describe the rates
of change of both nutrient and organism in the culture vessel. Simply put, the equations
describe the rate of change of nutrient as inflow minus outflow minus depletion due to
bacterial growth, and the rate of change of organism as growth minus outflow. It is
assumed in the chemostat model that bacterial growth is directly proportional to nutrient
availability only up to a limiting value [5]. Since the growth rate is a saturating function
of nutrient concentration, this rate typically incorporates Michaelis-Menten kinetics. The
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growth rate is defined as

mS
where S is the concentration of nutrient, m is the
a+S'

maximum growth rate, and a is that value of S for which the growth rate is one-half of the
maximum. The equation defining the growth rate of the bacteria,
(growth rate) =

mS
a+S

--,

is known as the Monod equation [45,46]. The following are the differential equations
adapted from [45]. Parameters are defined in Table 4.

dS F
F
ImS
-=-So--S----x
dt V
V
r a+S

(3.1)

dx
mS
F
-=--x--x
dt a+ S
V

(3.2)

S(O)

~

0, x(O) > O.

Table 4 Parameters in the Chemostat Model
Parameter

Units

Description

S

mass/volume Concentration of nutrient in culture vessel at time t

x

mass/volume Concentration of organism in culture vessel at time t

So

mass/volume Concentration of nutrient in feed vessel

y

none

Yield constant reflecting nutrient depletion due to
bacterial growth

m

l/time

a

mass/volume Michaelis-Menten constant

F

volume/time

Volumetric flow rate

V

volume

V olume of culture vessel

Maximum growth rate of organism

Using the simple chemostat containing only nutrient S and a single species x,
many different scenarios may be investigated by introducing additional elements into the
chemostat environment.

For example, a researcher may introduce two different

organisms XI and X2 which compete for nutrient S into the culture vessel in order to study
the competition between the two organisms. The model of the chemostat in this case
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would consist of three differential equations, one each for S, Xl, and X2. Another variation
of the chemostat may involve nutrient S and organism
predators on

X,

say, y and z.

X,

as well as two additional

The model of this chemostat contains four differential

equations. (The equations for these two scenarios are not shown here but can be found in
[45].)

Lenski and Hattingh propose another variation of the chemostat in [49]. They
present a model which investigates the dynamics of two species competing for nutrient in
the presence of a substance which inhibits the growth of one of the species but not the
other. The growth-inhibiting substance is input into the environment from an external
source, as opposed to being produced by one of the competing species. The former
scenario is called an external inhibitor problem, while the latter is an internal inhibitor
problem [47]. The internal inhibitor problem will not be addressed here. The model by
Lenski and Hattingh can be used to study the situation where the growth-inhibiting
substance is a bacteriostatic antibiotic, one species is susceptible pathogenic bacteria, and
the other is resistant pathogenic bacteria.
While the inhibitor in the model by Lenski and Hattingh lessens the reproductive
rate of the susceptible organism, Hsu, Li, and Waltman present a chemostat model in [47]
with a slightly different type of inhibitor. In this model, two organisms compete for
nutrient in the presence of an inhibitor which is lethal to the susceptible organism (rather
than merely limiting its reproductive rate) but is taken up by the resistant organism with
no damaging effect. A bactericidal antibiotic is representative of this type of inhibitor.
We denote the nutrient as S, the susceptible organism as

X,

the resistant organism as y,

and the inhibitor as P; the model for this type of chemostat follows (adapted from [47]).

dS
dt

So- F S-~ mlS x __
l m2S y
V
V
rl Gl + S
r2 G2 + S

=F

(3.3)

dx
mlS
F
-=--x--x-ifx
dt GI +S
V

(3.4)

m2S
F
y--y
m+S
V

(3.5)

dy

-=

dt

dP F
F
oP
-=-P,,--Py
dt
V
V
K +P

(3.6)

S(O),P(O);:::: O;x(O),y(O) > o.
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In the above equations, mi, ai, Yl correspond to x, and m2, a2, Y2 correspond to y,
and are analogous to definitions of m, a, and y in equations (3.1) and (3.2) above, as are F
and V. So and Po are the input concentrations of nutrient and inhibitor, respectively. b is
the uptake of inhibitor by y, K is a half-saturation parameter for inhibitor uptake, and ( is
a constant of proportionality representing the rate at which P kills x. Since y actually
removes P from the environment, it is a detoxifying organism.
The chemostat has been suggested for use as a model in clinical applications other
than bacteria and antibiotics. For example, Edelstein-Keshet [5] outlines a simple system
of two equations that can be used to describe the course of chemotherapy in a patient who
is receiving drugs via an internal infusion pump. If, say, the patient has a tumor in the
liver, then Edelstein-Keshet views the infusion pump as analogous to the feed bottle of
the chemostat and the liver as a type of culture chamber. Tumor cells and drug units are
mixed in the liver. She suggests the following as an outline for the system of equations:
dN
dt
de
dt

= (growth rate of cells) - (drug induced death rate)
= (rate drug infused) - (rate of cell uptake) - (rate of removal by circulation)

where N is the number of tumor cells per unit blood volume and e is the number of units
in circulation per unit blood volume.
3.2 The One Bug-Two Drug Model of the leu

The

leu

is similar to the chemostat with inhibitor described by Hsu, Li, and

Waltman in several respects, which justifies its use as a basis for the model. However,
there are some key differences which are reflected in the equations of the
The

leu

model.

leu itself may be viewed as the culture vessel, or bacterial growth chamber, of a

chemostat.

The patient admissions and discharges represent the inflow and outflow. If

we assume that the

leu is always operating at capacity, then the volume is constant; i.e.,

inflow equals outflow, as in the chemostat. The patient hosts provide nutrient for the
bacteria. There are two inhibitors in the

leU, namely, the antibiotics being administered

to the patients, although the two different antibiotics are not present simultaneously. The
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inhibitor is input from an external source, so this may be classified as an external
inhibitor problem.
In the six differential equations that make up the One Bug-Two Drug model, Al
and A2 represent the two antibiotics being cycled in the leU, while

13ss

represents the

subpopulation of the total bacterial population which is susceptible to both Al and Ab B rs
is the subpopulation resistant to Al but susceptible to A2,
susceptible to Al but resistant to A2, and

Brr

Bsr

is the subpopulation

is the subpopulation resistant to both AJ and

A2. Before the equations are given, we briefly discuss the differences in the chemostat
model and leu model which lead to the differences seen between equations (3.3)-(3.6)
and the equations below.

leu Model Assumptions:
1. In the chemostat model, microorganisms increase

In

number solely by

reproduction. In the leU, bacteria not only reproduce, but also enter the leu via patient
inflow.
2. If a patient is infected with a strain of bacteria resistant to a particular
antibiotic, then the patient is not treated with that antibiotic. As a result, the equations for
the rates of change of Al and A2 do not contain terms reflecting "uptake" by the resistant
organism (see equation (3.6)).
3. In the chemostat, the inhibitor may exit the culture vessel via outflow. In the
ICU, the antibiotics are removed via patient excretion.
4. Growth of bacteria in the leu is not limited by the amount of nutrient
available as it is in the chemostat. We assume that in the leU, resource is superabundant.
Thus, the growth rate for the bacteria in the leu model does not incorporate the amount
of nutrient present. Bacterial growth in the leu is assumed to be logistic [5,45].
5. Bacteria may gain resistance to an antibiotic while that antibiotic is in use (a
process called "mutation"), and lose resistance when the antibiotic is no longer in use
("reverse mutation").

The equations for the rates of change of the four bacterial

subpopulations contain terms accounting for the ability of the bacteria to switch from one
subpopulation to another, with some restrictions (see Assumption 6, below).
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6. For our purposes, a full cycle is defined as
240 days, where A I is in use for the first 120 days and

A2 is in use for the second 120 days. During one-half

of a cycle, bacteria may undergo one mutation, one
reverse mutation, or neither of the two. Furthermore,
the type of mutation or reverse mutation which may
occur depends on the antibiotic in use. Bacteria may
gain resistance to a particular antibiotic only if that
antibiotic is in use, and lose resistance only if it is not
In

use.

Figure 1 at right shows the possible

mutations/reverse mutations. Note that this assumption

Figure 1 Pathways of
Bacterial Mutation and
Reverse Mutation

places restrictions on the ability of bacteria to move
from one subpopulation to another. For example, doubly susceptible bacteria require a
full cycle to become doubly resistant, as two mutations must occur, one during each half
cycle.
7. Rather than one inhibitor being present at all times as in the chemostat, in the

ICU, Al is in use if and only if A2 is not in use. To incorporate this effect into the model,
an idealized unitless drug indicator function, d(t), is defined. The drug indicator function
is defined as one if Al is in use and zero if A2 is in use (see Table 5). The function is
time-dependent. This function will be made continuous before solving the system (see
Section 4.2).
8. The antibiotic is not input at a constant rate as is the inhibitor in the chemostat
model. Rather, the concentration of antibiotic depends on exactly two factors: whether
the drug is in use at that time, and the number of bacteria which are susceptible to that
antibiotic at any given time, up to some limiting value (i.e., amount of antibiotic present
in the

leu reaches a maximum value when that antibiotic is in use and every patient is

infected with susceptible bacteria).

Thus the rate of increase of antibiotic displays

Michaelis-Menten kinetics. The half-saturation parameter in this rate is the concentration
of bacteria in the

leu

at which the concentration of antibiotic is one-half of the

maXImum.
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The One Bug-Two Drug model follows, with parameters defined in Table 5.

BlOlal
Fin"
-dB;s = rs.,Bss(l- ) + - Bss ~

dBrs
dt

-

dB"

-

~

dBrr

-

~

dAI
dt

(3.7)

Biotal
Fin"
Foul
K
V
V
- /31(1- d(t))Brs + /32d(t)Brr - ;2(1- d(t))Brs

(3.8)

Blolal
Fin
FOUl
K
V
V
+ /31(1- d(t))Brr - /32d(t)Bsr - ;ld(t)Bsr

(3.9)

= rrsBrs(1--)+-Brs--Brs+ ald(t)Bss-a2(1-d(t))Brs

= rsrBsr(1- - ) + -B.lr - -Bsr - atd(t)Bsr + a2(1- d(t))Bss
A

Blolal
Fin"
FOUl
K
V
V
- /31(1- d(t))Brr - /32d(t)Brr

(3.10)

pl(Bss + Esr) d( )
A
t -yl I
KI + B,s + Bsr

(3.11 )

= rrrBrr(1---) +-Brr --Brr + atd(t)Bsr + a2(1- d(t))Brs

-=

dA2
dt

Foul
Bss - atd(t)B,·, - a2(1- d(t))Bss
K
V
V
+ /31(1- d(t))Brs + /32d(t)Bsr - ;ld(t)B.,s - ;2(1- d(t))Bss

= p2(Bss + Brs)
K2

(1- d(t)) - Y2A2

+ Bss + Br.,

(3.12)

Bs.,{O), Brs(O), Bsr(O), Brr(O) ;::: 0; AI(O), A2(0) ;::: 0
(Bu(O) > 0 for some subpopulation).

Before we proceed to the analysis of the model, we address two valid criticisms of
the chemostat as a model for the ICU. The first is that in the chemostat model, it is
assumed that the bacterial growth chamber is kept well stirred. In the clinical setting,
obviously it is not desirable that the contents of the ICU be "well stirred." In fact, while
cross-contamination does occasionally occur, resulting in the nosocomial infections
discussed in Chapter II, hospital personnel generally go to great lengths to prevent this.
The second criticism is that the One Bug-Two Drug model contains no equation
reflecting rate of change of nutrient. This difference is not significant, because "nutrient"
is assumed to be superabundant.

Note that Edelstein-Keshet's system of equations

describing the interaction of drugs and tumor cells in the liver contains no nutrient
equation.

In addition to these considerations, the conditions in the ICU merit a
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Table 5 Parameters in the One Bug-Two Drug Model

Parameter
B ss, B rs, B sr, Brr

Units

Description

CFU/mL

Concentrations of each of the four types of bacteria
in the ICU;

Btotal

is the sum of B ss,

B rs, Bsn

and B rr.

~glmL

Concentrations of each of antibiotics 1 and 2 in the ICU

K

CFU/mL

Carrying capacity of the total bacterial population

V

mL

Volume oflCU

CFU/mL

Concentrations of each of the four types of bacteria

A I ,A 2

,..

Btotal

,..

"

"

B." , Br, , Bsr , Brr

in a typical incoming ICU patient
r ss, rrs, r sr, rrr
Fin, F out
aI,

a2

I/time

Growth rates of each of the four types of bacteria

mLitime

Volumetric patient inflow/outflow rates

lItime

Mutation rates; rates at which bacteria gain resistance
to Al and A2, respectively

I/time

Reverse mutation rates; rates at which bacteria
lose resistance to Al and A 2 , respectively

l/time

Killing rates; rates at which susceptible bacteria are
killed by Al and Ab respectively

PI, P2

~g/(mL-time)

Maximum concentrations of A I and A2, respectively

CFU/mL

Michaelis-Menten constant; concentration of
bacteria susceptible to AI, A2 at which dosage of
AI, A2 is one-half of the maximum, respectively

YJ,

Y2

d(t)

(idealized)

I/time

Elimination rate constants for A I and A 2 , respectively

none

Drug indicator function:
1 for 0 < t ~ 120, 240 < t

~

360

o for 120 < t ~ 240, 360 < t ~ 480
slightly different view of the chemostat which render a nutrient equation unnecessary, as
explained below.
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Let us return to the model of the simple chemostat, where no inhibitor is present
(equations (3.1) and (3.2)). The rate of change of antibiotic in the ICU is analogous to
the rate of change of organism in the simple chemostat in several ways. The similarities
are listed in Table 6. (The chemostat assumptions are given by Edelstein-Keshet in [5].)
Essentially, if one takes this point of view, the ICU is no longer viewed as a chemostat
with inhibitor. Instead, it is viewed as a simple chemostat. The antibiotics in the ICU
correspond to the organisms in the culture vessel of the chemostat, and the bacteria in the
ICU are analogous to "nutrient," the substance whose availability (or lack thereof) causes
the amount of antibiotic to increase or decrease.

While this is a somewhat

unconventional view of the chemostat, it closely follows Edelstein-Keshet's vision of the
chemostat as a model for chemotherapy and it accurately describes the interplay between
bacteria and antibiotics in the ICU in several ways.

Table 6 Comparison of Simple Chemostat and ICU

Chemostat

ICU
The increase or decrease in antibiotic

The growth rate of microorganism

concentration depends on number of

depends on nutrient availability.

susceptible bacteria present in the ICU.
Susceptible bacteria decrease in number
Nutrient depletion occurs continuously as
a result of reproduction by microorganism.

Rate of growth of microorganism increases
with nutrient availability only up to some
limiting value; microorganism growth rate
and nutrient consumption is assumed to be
a saturating function of nutrient

continuously as a result of increase in
antibiotic concentration.
Rate of "growth" of antibiotic concentration increases depending on number
of susceptible bacteria only up to some
limiting value; antibiotic concentration
and bacterial killing is assumed to be a
saturating function of bacterial

concentration.

concentration.

Nutrient is continually added to the

Susceptible bacteria continually enter the

culture vessel via inflow.

ICU via patient admission.
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CHAPTER IV
ANAL YSIS OF MODEL

"The exploration of the conditions which do, and which do not, influence a
phenomenon is part of the early experimental exploration of afield. "
Eugene P. Wigner,
The Unreasonable Effectiveness of Mathematics in the Natural Sciences
[50]

4.1 The LHS and LHS/PRC Analysis Techniques
It is often the case in modeling biological phenomena that there is a significant

amount of uncertainty as to the true values of the inputs that will be used to evaluate the
model outcome. In some cases, an input value may not be constant, but may vary within
a known range of values. In other cases, it may be impossible to estimate the input value
(or even range of values) to the desired degree of accuracy. For example, Blower and
Dowlatabadi [9] present a model of HIV transmission in which one of the parameters is
the rate of needle sharing among IV drug users; certainly it is difficult to pinpoint an
accurate value for such a parameter.
The purpose of uncertainty analysis is to evaluate the variability of the model
outcome due to changes in the input values. The behavior of a deterministic model such
as the One Bug-Two Drug model is determined solely by its time evolution equations and
input values (initial conditions and parameter values), so uncertainty analysis will
produce quantitative information about the imprecision of the outcome of a deterministic
model. Sensitivity analysis extends uncertainty analysis by identifying the input values
which have the greatest effect on model results. Sensitivity analysis is instrumental in
both interpreting model results and guiding future research efforts [51].
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The LHS (Latin Hypercube Sampling) uncertainty and LHSIPRC (Latin
Hypercube Sampling/Partial Rank Correlation) sensitivity analysis techniques were used
to analyze the One Bug-Two Drug model in this paper.

The LHS technique was

proposed by McKay, Conover, and Beckman in [52]. They compared three methods of
selecting, or "sampling," input values: random sampling, stratified sampling, and Latin
hypercube sampling. Their results proved that unbiased estimates of the sample mean
could be obtained with the LHS design, and that the estimator of the mean using the LHS
design was clearly superior to both the random sampling and stratified sampling designs
when using the same number of model simulations for each method. The LHS design has
also been proven to be an extremely efficient design. Seaholm, et al. [53] compared the
LHS technique with a full factorial (FF) fixed point sample and found that an FF design
with over 14 times as many samples as the LHS design produced approximately the same
predictive ability and information about model uncertainty.

While LHS has its

advantages over other methods, one drawback is that it does not evaluate the effects of
individual input values on the model outcome [54].

For this reason, partial rank

correlation coefficients are often used in combination with LHS [9,54,55]. The use of the
partial rank correlation coefficient (PRCC) is not uncommon in sensitivity studies [51],
but it is not informative in cases where there exists a nonmonotonic relationship between
variables. Such relationships must be investigated by other means.
As outlined in [9], there are seven steps in the LHS and LHSIPRC techniques:
1. Suppose that the model has k uncertain input values. Assign a probability
distribution function (pdf) to each of these k input variables.

In the case of a

deterministic model, this means that all parameters and initial conditions which are not
known constants are assigned probability distribution functions. These pdf s should be
obtained from a search of relevant literature, experimental data, or other methods
whenever possible. O'Neill, et al. recommend that a parameter be assigned the triangular
distribution when the true distribution of the parameter is unknown, but a minimum,
maximum, and most likely value for the parameter are known [56].
2. Determine the number of simulations, N.

The inequalities N>4k/3 and

N2:(k+ 1) must be satisfied [9], although there is no formula to determine an optimal value
forN.
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3. Divide the range of each of the k parameters into N strata of equal probability.
(The area under the curve of each interval is now lIN.) For each of the k parameters,
select exactly one value at random from each of the N intervals. For example, if x is a
parameter, then the set

{Xl, X2, •.. , XN}

represents the N values selected for x, where

selected from the first equiprobable interval,

X2

Xl

is

is selected from the second equiprobable

interval, and so on. Note that in this step of the LHS scheme, the entire range of each
parameter is represented. Thus sampling occurs over all of the sample space, which is one
of the advantages of the LHS technique.
4. Create the LHS table. The LHS table is an Nxk matrix, where columnj (j = 1,
2, ... , k) is a random permutation of the N values selected for the jth parameter in step 3,
above. Each row of the LHS table is a k-tuple which will be used as an input vector for
exactly one simulation of the model.
5. Perform the N simulations of the model. Row i (i = 1, 2, ... , N) of the LHS
table is the input vector for the ith run of the model.
6. Perform uncertainty analysis.
7. Calculate partial rank correlation coefficients (PRCC's) between each
parameter and each outcome variable; perform sensitivity analysis.

4.2 Uncertainty Analysis

We now proceed to the implementation of the LHS uncertainty analysis procedure
for the One Bug-Two Drug model.

First, probability distribution functions must be

assigned to each parameter. A search of the medical literature did not produce any
specified pdfs for the input variables; however, in most cases a minimum value and
maximum value could be ascertained from the literature. The minimum and maximum
values for the initial conditions and some of the parameters were established through
personal communication with Dr. D.T. Tsukayama, an infectious disease specialist at
Hennepin County Medical Center in Minneapolis, Minnesota. All pdf s are assumed to
be triangular, with the most likely value (peak) at the midpoint between the minimum and
maximum values. The pdfs are defined in Table 7, accompanied by a discussion of the
biological justifications for the definitions.
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We assume that initial conditions are zero for both Ai and A2, as the appropriate
amount of antibiotic will be determined according to whether the antibiotic is in use and
susceptible bacteria are present in the ICU. The minimum and maximum values of the
total initial bacterial concentration were established by assuming that 6-12 patients are
infected with bacteria at time t = 0, and of these bacteria, 80% are doubly susceptible, 9%
are singly resistant to either Ai or A 2, and 2% are doubly resistant. Thus initial conditions
for concentrations of bacterial subpopulations are
Bss(O) = 0.8

x

Brs(O) = Bsr(O)

BtotaAO),

= 0.09 x BtotaAO), and

Brr(O) = 0.02 x BtotaAO),

where BtotaAO) is total initial bacterial concentration.

The mInImUm count per site

necessary for infection to occur was assessed by Dr. Tsukayama. Minimum and
maximum values of Bss, Brs, Bsr , Brr were calculated in a similar fashion. A plausible
range for the maximum carriage of bacteria in host tissue was established, and the
minimum and maximum values of the carrying capacity (K) were found by assuming that
this concentration of bacteria was present in all of the 12 I CU patients. The range of the
growth rate of doubly susceptible bacteria, r ss , was found in [57].
literature provided no information about the growth rates rrs,

r sr ,

A search of the

and rrr. However, it has

been established that gaining resistance imposes a fitness cost on the bacteria [43]. For
the purpose of this analysis, it was assumed that the growth rate

rss

decreases by 20%

with a single resistance-conferring mutation and by 40% with two such mutations;
maximum and minimum values for the three remaining growth rates were calculated
based on this assumption.
The range of values for patient inflow rate, Fin, was based on the assumption that
3-5 patients are admitted to the leu each day; furthermore, the ICU in this case is kept at
capacity, so F out and Fin are equal. Because of this assumption of equality, Fin and Fout
will both be referred to as simply F, the patient inflow/outflow rate, in the analysis of the
model. The mutation rate for ciprofloxacin, ai, was found in [58]. While an exact range
of values for the mutation rate for piperacillinltazobactam could not be found, it is certain
that the resistance potential for ciprofloxacin is high but the resistance potential for
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Table 7 Probability Distribution Functions for Input Variables
Min.

Min.

Max.

a2

1. 5625 x 10- 7

3.125x10-6

BI

7.8125 x 10-8

1. 5625 x 10-6

B2

3 .90625 x 10-8

7.8125 x 10-7

Max.

Initial

Parameters

Condition

(continued)

Btotal(O)

3

5.0x10

7

LOx 10

Parameters
12

K

LOx 10

Btolal

1. 0 x 10

LOx 10

4

15

LOx 10

7

~I

0.96

0.99
0.99

rss

36.97

45.36

~2

0.96

rrs

29.576

36.288

KI

4.45x10

3

rsr

29.576

36.288

K2

4.45x10

3

rrr

22.182

27.216

YI

1.92

7.68

F

5.82x10

Y2

12.96

19.2

5

1.15 x 10

3.125x10-7

aj

6

4.45x10

6

4.45 x 10

6

6.25x10- 6

piperacillin/tazobactam is low [22,27,28,29,59]. For the purpose of model analysis, we
assume that the minimum and maximum values for

a2

are approximately one-half of the

minimum and maximum values for ai. Reverse mutation rates rarely, if ever, appear in
the literature; in this case no reverse mutation rates could be found. Nevertheless, loss of
resistance generally occurs more slowly than development of resistance [31]. Here we
assume that reverse mutation takes longer than mutation by approximately a factor of
four, so maximum and minimum values for BJ and B2 were determined using this
assumption. The killing rates,

~I

and 6, were found in [60]. The parameters PI and P2 are

constants. The maximum amount of antibiotic is present when the ICU is at capacity and
every patient is being dosed daily, so PI and P2 are determined by multiplying the amount
of antibiotic in a single daily dose by the maximum number of patients in the ICU. Here
PI = 12 x 800 = 9600 Jlg/(mL-time) and

P2 = 12

x

13,500 = 162,000 Jlg/(mL-time) [36].

The minimum and maximum values for the half-saturation parameters KJ and K2 were
found by calculating the range of bacteria present in the ICU when one-half of the
patients are infected with susceptible bacteria. Ranges for elimination rate constants YI
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and

}'2

were found in [61,62,63] and in consultation with Dr. Tsukayama. Finally, the

volume of the ICU, V, is a constant, and was defined for this analysis as the sum of the
volumes of the patients, i.e., V is 2.52

x

106 mL.

Several of the input variables will not be assigned pdf's (the

SIX

initial

conditions, Bss, Brs, B.I'r , Brr, Foul, PI, P2, V) for the reasons discussed above, although
A

pdf's will be assigned to Blotal(O) and BIotal. As a result, the number of input parameters to
be sampled is 18. The number of simulations is set at 200, a number which satisfies both
inequalities given in step 2 of Section 4.1. For each of the 200 simulations, we assume
that ciprofloxacin was the drug in use for the first and third 120-day periods, and
piperacillinltazobactam was the drug in use during the second and fourth 120-day
periods. The outcome variables are evaluated at time t = 480 days, at the completion of
two full cycles.
All of the relevant calculations in steps 3 through 7 of the LHS uncertainty and
LHS/PRC sensitivity analysis (division of parameter ranges into equiprobable intervals,
permutations of sampled values, evaluation of outcome variables for each of the 200
simulations, etc.) were performed with the aid of the Mathematica system. The computer
program that was used to perform the model analysis was developed specifically for this
paper, with [64] serving as a valuable resource in the writing of the program. In order to
run the model simulations with Mathematica, the drug indicator function was redefined.
While the definition of the drug indicator function in Table 5 represents an idealized
vision of the cycling strategy, redefining the function as a continuous one is a better
representation of reality and aids computing capability in obtaining a numerical
approximation for the solution of the system of differential equations. The redefined
drug indicator function incorporates a 24 hour period at days 120, 240, and 360 during
which usage of one drug decreases to zero and usage of the other drug increases to the
appropriate level.

The computer code which comprises this program, including the

redefined drug indicator function, can be found in Appendix 1.
The uncertainty analysis for the antibiotic outcome variables (see equations (3.11)
and (3.12)) was not particularly informative. At time t = 480, Al has been out of use for
120 days, so the concentration of this antibiotic in the ICU should be very low. The
uncertainty analysis reveals this to be true, as the mean and variance of the outcome
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values of AJ are both approximately zero. The mean of the outcome values of A2 is
10,139 /lg/mL.

This is a somewhat low concentration of antibiotic, implying a low

concentration of bacteria susceptible to A 2 . The results of the uncertainty analysis for the
outcome variables related to bacterial density, (equations (3.7)-(3.10», are shown in
Table 8 and Figure 2, with interpretation of results given in Chapter 5.

The LHS

uncertainty analysis showed that the variances of the outcome variables are fairly high,
indicating a high degree of model imprecision due to imprecise parameter estimation.

Table 8 Descriptive Statistics for Outcome Variables at Time t = 480 days

Brs

Bss
Minimum

4.14099

x

Bsr

Brr

10

13
14

291,951

6.38529

x

10

147,168

1.33536

x

9.33395

x

Maximum

9,85409

x

10

Mean

4.96502

x

10 14

Variance

4.12099

x

1028

1.18013

12,603.1

3.74766

x

109

x

10

9

61,245.4
1.92631

x

10 11

10 10

1.78357

x

109

10 19

2.22959

x

1020

10
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Figure 2 Frequency Distributions for Values of Outcome Variables (a) Bss, (b) B rs ,
(c) Bsn and (d) Brr at time t = 480 days.
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4.3 Sensitivity Analysis

Partial rank correlation coefficients between each sampled input variable and each
outcome variable were calculated using formulae from [9,65,66] and the Mathematica
program. A complete description of the methods by which PRCC's were calculated is
given in Appendix 2. A PRCC may range in value from -1 to 1.

The greater the

magnitude of the PRCC between a parameter and an output variable, the more impact the
parameter has on the outcome of the variable. A positive value of the PRCC indicates
that as the input value increases, the output value increases. A PRCC with a negative
sign denotes an inverse relationship between the input and output values. The PRCC's
for the antibiotic outcome variables are not of interest here, as few parameters affect the
outcome of antibiotic concentration. For each of the four outcome variables related to
bacterial density, the PRCC's with significance levels 0.001 and 0.05 were identified.
Results are shown in Table 9 and discussed in Chapter 5.

Table 9 Partial Rank Correlation Coefficients
B rs

Bss

PRCC
0.99%

Earameter

K

BIOtal

0.99 t

F

-0.31 t

F

0.88 t

rrs

0.18 t

rss

-O.l6 t

Qarameter

~

Bsr

PRCC

Brr

PRCC
0.87%

}2arameter

K

F

PRCC
-0.69 t

a2

0.86+

rss

-0.42+

rss

-0.64+

rrr

0.41 +

rsr

0.63+

B'll'al

O.17 t

F

-0.52+

parameter

Results are significant at the 0.05 level
or 0.001 level (t).
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C)

CHAPTER V
CONCLUSIONS

"Anything that is produced by evolution is bound to be a bit of a mess. "
Sydney Brenner,
Quoted in Why is development so illogical?

[67]

In this chapter we begin with a discussion of the results of the uncertainty and
sensitivity analysis of Chapter 4, accompanied by an examination of the behavior of the
model, then briefly discuss experimental data, and conclude with some suggestions that
will be useful in guiding future work with the One Bug-Two Drug model.
The behavior of the model was fairly stable in each of the 200 simulations; no
chaotic behavior was observed. In order to gain a clearer understanding of the model, a
simulation was performed in which each input variable (both parameters and initial
conditions) was assigned the value of the mean of its pdf (see Table 7). The model's four
outcome variables relating to bacterial density were plotted with respect to time. The
results are shown in Figure 3. In the case of the first three variables, Bss, B rs , and Bsr , the
bacterial concentration quickly reaches a maximum or minimum value during each 120
day period and remains at that value until the next drug is cycled into use. The fourth
variable, Bm behaves somewhat differently. At the beginning of each 120 day period, the
concentration of Brr quickly rises to some peak value, and then declines to a minimum
value for the remainder of the 120 day period. The peak value of Brr at day 240 is much
lower than the peaks on days 120 and 360 and cannot be seen in Figure 3 due to the scale
of the graph. The peak occurring on day 240 is shown in Figure 4. The scale of the
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graphs in Figure 3 also makes it difficult to see the minimum values of the outcome
variables. Although they appear to be zero in each case, in fact, the minimum bacterial
concentrations of these variables remain above zero. Minimum values for Bss , Brs , Bsr and

Brr are approximately 1.129 x 106 , 1.27 x 10 5 , 9.97 x 104 , and 8 x 104 CFU/mL,
respectively, in the simulation at mean input values. While maximum and minimum
values may vary for each of the 200 model simulations, the behavior seen in Figure 3 is
roughly representative of the behavior seen in each simulation .. The nonzero minimum
values for the model indicate that the infections in the ICU are not clearing. This points
to a model deficiency, as there will be times when no P. aeruginosa infections are present
in the ICU in reality.
The frequency distributions of the outcome variables in Figure 2 show that the
outcome values for Bss and Brs are approximately symmetric about the mean, but the
outcome values for Bsr and Brr are right-skewed. In the case of B rr , 197 of the 200 model
simulations produced outcome values in the lowest tenth of the interval between the
minimum and maximum outcome values for Brr. The three model simulations which
yielded outcome values outside of this range are attributed to the coupling of very high
input values for the growth rate rrr with very low values for the patient inflow/outflow
rate F. (The implications of these input values on the outcome of Brr will be discussed
later in this chapter.) A high concentration of Brr is likely to contribute to a higher
concentration of Bsr , as a greater number of bacteria are losing resistance to AI and
moving from sUbpopulation Brr to subpopulation Bsr at time t = 480, after A2 has been in
use for 120 days.
The use of partial rank correlation coefficients in the sensitivity analysis allows us
to determine which parameters are most responsible for producing the variability in the
output values.

Some of the results obtained in the sensitivity analysis of the One Bug-

Two Drug model (see Table 9) are fairly obvious, while others are more surprising. For
example, the PRCC's of rss with respect to the bacterial subpopulations Brs , Bm and Brr
are negative. This is probably due to the fitness advantage of doubly susceptible bacteria
[43]; when Bss makes up a larger portion of the carrying capacity, there is less "room" for
the other types of bacteria. Note also that the positive correlation between the carrying
capacity K and Bss is very high. At time t = 480, the concentration of Bss is being reduced
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by patient outflow (F), bacterial killing by A2 ('2), and mutation (CX2).

However,

sensitivity analysis indicates that patient outflow has a greater effect on the outcome than
either killing or mutation.
The results of the sensitivity analysis become more interesting in studying the
behavior of B rs and

B sr .

At time t = 480, the concentration of B rs is at a minimum, so the

growth term in equation (3.8) containing the parameters
outcome. The PRCC of K with respect to

B rs

rrs

and K has little effect on the

was not significant, and the PRCC of rrs

with respect to Brs shows a relatively small positive correlation. Hence the concentration
increases primarily through patient inflow, as evidenced by the strong positive correlation
of both BIola! and F with respect to

B rs .

Mutation, reverse mutation, and killing rates did

not have a significant effect on the outcome of Brs , possibly because Brs concentration is
very low at day 480. For the outcome variable Bm

CX2

is a significant parameter because

A2 has been in use for the past 120 days, so the concentration is increasing due to

mutation of Bss , a bacterial subpopulation which is at fairly high levels at day 480.
Growth rate

rsr

and carrying capacity K are also clearly important, since the concentration

of Bsr is high at time t

=

480. Note that the concentration of Bsr has not been reduced

through bacterial killing by A2 because of its resistance, so we see a strong negative
correlation between F and B sr , indicating that this subpopulation is being reduced
primarily through patient outflow. Although

Bsr

is losing resistance to AI, reverse

mutation rate 81 does not have a significant effect.
Before discussing the sensitivity analysis results for B rr , we note that the
significance of the input variables often varies with respect to time. Table 10 shows a
comparison of the PRCC's of selected parameters with respect to

B rs

and

Bsr

at days 360

and 480. Consider the results of Table 10 in light of the model behavior shown in Figure
3. Here it is clearly evident that when bacterial concentration is at a maximum, growth
rate and carrying capacity are more strongly correlated with bacterial outcome than when
bacterial concentration is at a minimum. Note also that the significance ofthe parameters
varies depending on the drug that is in use. For example, the effect of mutation rate
the outcome value of Bsr is insignificant at time t

=

360, because

AJ

CX2

on

has been in use for

the previous 120 days. In addition, the comparison of PRCC's indicates that when
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Table 10 Comparison of Partial Rank Correlation Coefficients with respect
to B rs and Bsr at Times t = 360 and t = 480 days
B rs

t = 360

t = 480

Blolal

-0.05

0.99

F

-0.36

rrs

K

Bsr
~

t = 360

= 480

t

BIOtal

0.97

0.09

0.88

a2

-0.04

0.86

0.23

0.18

rsr

0.22

0.63

0.99

0.11

F

0.76

-0.52

~l

-0.13

-0.03

K

0.15

0.87

bacterial concentration is low, the primary means of increase in concentration is via
patient inflow.
The sensitivity analysis results at time t = 480 for Brr (Table 9) show that decrease
in the concentration of

Brr

occurs primarily through patient outflow (F). The double

resistance of Brr ensures that no bacterial killing occurs, which is the reason for the strong
negative correlation between F and Brr . Reverse mutation rates have little effect on the
outcome. The positive correlation of a2 with respect to Brr is greater in magnitude at time
t = 360 (PRCC 0.59) than at time t = 480 (PRCC 0.12) because the concentration of Brs is
higher at day 360, when A2 is first cycled into use. After 120 days, the Brs class has
dwindled as a result of bacterial killing by A2, so the impact of mutation rate a2 on the
outcome value of Brr has decreased.

Other parameters in Table 9 have a fairly

predictable effect on the outcome value of Brr (growth rate, etc.). The PRCC's for F and
rrr

with respect to Brr at time t = 480 indicate that the combination of a very low value for

F and very high value for

rrr

produces a large outcome value for Brr , which was the case

in each of the three model simulations discussed earlier in this chapter.
A particularly unexpected finding of the sensitivity analysis is that mutation,
reverse mutation, and killing rates generally have less effect on the model outcome than
patient inflow/outflow, growth rates, carrying capacity, and bacterial concentration in the
typical incoming patient. The pdfs of some of the parameters identified by sensitivity
analysis as very influential ones, such as K and Blolal, are based on estimates of the
possible range of bacterial concentration in patients. These estimates vary widely. The
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bacterial concentration in a single patient may range from 104 CFU/mL to 10 15 CFU/mL
[68].

Edelstein-Keshet [5] notes that the difficulty in determining concentration per

patient occurs with viral infections as well as bacterial, writing that " ... total viral
population ... may range over several orders of magnitude in individual hosts." (p. 243)
The variability is so large that these parameters tend to dominate the model outcome.
We now tum our attention to a discussion of the data set obtained from the
clinical trial performed at Hennepin County Medical Center (HCMC).

The task of

matching the data to the model output has proven to be a difficult undertaking. In the
clinical trial at HCMC, isolates were collected from all patients in the ICU approximately
once a week. We are only concerned here with those isolates testing positive for P.

aeruginosa. The isolates were tested for resistance or susceptibility to several antibiotics,
including those being cycled (ciprofloxacin and piperacillinltazobactam). The data set
gives the whole number of isolates per data collection day and the results of tests for
resistance on each isolate.

(No information about daily antibiotic concentration is

included in the data.) While the data measures number of isolates, the model measures
bacterial concentration.

Converting the data from the clinical trial from number of

isolates to bacterial concentration involves a fair amount of speCUlation, for reasons
discussed in the previous paragraph.

In addition, data analysis has thus far been

inconclusive in determining whether there are any cyclic patterns occurring as a result of
antibiotic usage.
Nevertheless, for the purpose of comparison of the data and model output in this
paper, we have attempted to convert the data from number of isolates per data collection
day to bacterial concentration per data collection day. Each isolate was classified as a
member of exactly one of the four bacterial subpopulations Bss, Brs , Bsr , or Brr , depending
on the results of the resistance testing.

Then a plausible value was chosen for the

bacterial concentration in each patient from which an isolate was taken. In this way
bacterial concentrations for each of the four subpopulations were derived for the data
collection days. No information is available for the days in which data collection did not
occur. These bacterial concentrations were plotted with respect to time and are shown as
discrete data points superimposed on a simulation of the model in Figure 5. For the
model simulation in Figure 5, all parameter values were set at the means of their pdfs,
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Figure 5 Comparison of Model Output and Data from Clinical Trial

and initial conditions were chosen according to data from day 1 of the clinical trial. Note
that the change in initial conditions does not appear to change the behavior of the model.
This is not surprising, as the initial condition for bacterial concentration was not
identified as a significant input variable by the sensitivity analysis.
At this time the fit between the model and the data is not a good match. A second
data set is currently being collected at Utrecht University Medical Center in Amsterdam.
As we look ahead to continued work with the model, not only will more data become
available, but the model parameter values (such as mutation and reverse mutation rates)
will become available in the medical literature, as the problem of resistance is the focus
of much research in the medical community today" The difficulty in estimating patient
bacterial concentration also presents an obstacle that must be overcome before the model
can be used in the clinical setting. Nevertheless, when both data sets are available for
model comparison and parameter values can be assessed with less uncertainty, there will
be a marked improvement in the fit between the model and the data.
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Further model revisions will also facilitate a better fit between the model and the
data. The One Bug-Two Drug model currently classifies bacteria as either susceptible or
resistant. However, it may be more realistic to incorporate some type of intermediate
susceptible/resistant classification(s) into the model. In addition, the bacterial equations
(3.7)-(3.10) do not consider specific antibiotic concentration as a contributing factor to
resistance development beyond the simple on/off dynamics captured by the drug
indicator function. The medical literature indicates that the gain of resistance is often
concentration-dependent. Future model revisions may measure the complex interplay
between antibiotic concentration and resistance development more precisely by including
the fluctuating antibiotic concentration as a parameter in the bacterial equations.
The One Bug-Two Drug model is not ready for use as a predictive tool in the
clinical setting at this point, but once the data has been matched to the model output, the
model will be valuable in studying the effects of antibiotic cycling. For example, the
model can be examined to determine the optimal cycle length to minimize resistance, or
to examine the long-term effects of cycling.

It can also be used to investigate other

pathogenic bacteria, such as S. aureus, by redefining parameter values accordingly.
The study of the dynamics of bacterial gain and loss of resistance as a result of
antibiotic use is an area of research with the potential to save lives. As our understanding
of the principles of biomathematics grows, so will our ability to comprehend and
accurately model the dynamics of resistance. Ian Stewart writes in [2] that "our current
mathematical understanding of biology, admittedly, is fragmented, piecemeal, and open
to dispute - just as it is for any new science... I believe there may be a new kind of
mathematical theory out there in the intellectual darkness... if we can find it, it will
greatly illuminate some of the big puzzles of biology - development, reproduction,
ecosystem dynamics, evolution ... " (pp. xiii, 245; emphasis in original). Perhaps the key
to truly understanding the dynamics of resistance will be found after further work with
the model presented in this paper, or perhaps it lies instead in mathematical tools that are
only now in the earliest stages of development. In either case, the future is likely to hold
promising developments in the ongoing battle against bacterial infection.
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APPENDIX 1
Latin Hypercube Sampling with Mathematica
« Statistics 'Ccnti.nuousDistrihuticms'
« DiscreteMath 'Cad:ri.natorica. '

tmp:rotect[PDF, CDF, Quantile] ;
Clear [PDF, CDF, Quantile] ;
Off[NIntegrate: :pl.oss] ;

Off[NIntegrate: :s1woon] ;
Off[NIntegrate: :ncvb] ;
Off [ Finc:tRoot: : fmp] ;

IDF[TriDist[a_, b-.J

,X-.J :;;:

«4. Unitstep[x- a] • Unitstep[b- x)) I (b - a) "'2) •

( (x- a) • Unitstep[ (a + b) 12 - x] + (b- x) • Unitstep[x - (a + b) 12])
CDF[TriDis~[

(a-> ?NlDeric:Q, (b-> ?NlDeric:Q], (x-> ?N\Deric:Q] :;;:

Block [ {t} , NIntegrate[PDF[TriDist[a, b) , t] , {t, a, x}]]

Quantile[dist: TriDist[ (a-> ?NI.Deri.c:Q, (b-> ?NI.Deri.c:Q], (C{j?NlDericQ] :;;:
Whi.c:h[q~

1., b, qs 0., a, True,

Bl.ock[{x}, xl. F.i.ndRoot[CDF[dist, x] -q, {x, (2a+b) 13, (a+2b) 13},
MaxIteraticms ~ 100]] ]
PJ:otect[PDF, CDF, Quantile] ;
eqll:ipn:b[dist_, n_] :;;: Partiti.al[Table[Quantile[dist, kIn] , {k, 0, n}] , 2, 1] i
distparam[l] ;;: TriDist[ 6.104 , 12.107 ]

;

distparam[2] ;;: TriDist[loU, 1cf5] ;
distparam[3] = TriDist[104, 107 ] i
distparam [4] ::; TriDist[ 36.97, 45.36] i
distparam[5] :: TriDist[0.8.36.97, 0.8.45.36];
distparam[6J :;: TriDist[0.8.36.97, 0.8.45.36);
distparam[7J ::; TriDist[0.6.36.97, 0.6.45.36];
distparam [8J ::; TriDist[ 5.82. 105 , 1.15. 106] i
distparam[9] :: TriDist[3.125. 10-7 , 6.25.10- 6]
distparam[10] :: TriDist[1.5625. 10-

7

,

;

3.125.10- 6]

distparam[ll] :: TriDist[0.25. 3.125. 10-

7

,

;

0.25.6.25.10- 6 ] i

distparam[12] :: TriDist[0.25. 1.5625. 10-7 ,0.25.3.125.10- 6 ] ;

51

distparam[13] = TriDist[ .96, .99];
distparam[14] = TriDist[ .96, .99];
distparam[15] = TriDist[ 4.45.103, 4.45.106] ;
distparam[16] ;;; TriDist[ 4.45.103, 4.45.106]

;

distparam[17] = TriDist[1.92, 7.68];
distparam[18] ;;; TriDist[12.96, 19.2];
Do[int[i] = equiprob[distparam[i] , 200] , {i, 1, 18, 1}] ;
Do[sarrp1edva1ues[i] = Table[lWldan[Rea1, int[i] [[j)]] , {j, 1, 200}] , {i, 1, 18}]
Do[l.hsoolum[i] = RandaoPemutatial[sarrp1edva1ues[i)) , {i, 1, 18}]
l.hsoolumfunctian[n_,

k~

:= l.hsoolum[k] [[n)) ;

IBSTab1e = Array[l.hsoolumfunctian, {200, 18}] ;
Oo[a[i] = IHSTab1e[ [i, 1]] , {i, 1, 200}] ;
Oo[K[i] = IHSTab1e[ [i, 2] ] , {i, 1, 200}] ;
Do[Brotru.[i] ;;; IHSTab1e[ [i, 3]] , {i, 1, 200}] ;
Do[rss[i] = IHSTab1e[ [i, 4]] , {i, 1, 200}] ;
Do[rrs[i) = IHSTable[ [i, 5)), {i, 1, 200}] ;
Do[rsr[i] ;;; IHSTab1e[ [i, 6]] , {i, 1, 200}] ;
Oo[r]7[i] = IHSTable[ [i, 7]] , {i, 1, 200}] ;
Do[Fin[i] = IHSTab1e[ [i, 8)), {i, 1, 200}] ;
Do[Q1[i) ;;; IHSTab1e[ [i, 9] 1, {i, 1, 200}] ;
Oo[Q2[i] = IHSTable[ [i, 10)), {i, 1, 200}] ;
Oo[131[i] = IHSTab1e[ [i, 11]], {i, 1, 200}] ;
Oo[132[i] ::: IBSTab1e[ [i, 12)] , {i, 1, 200}] ;
Oo[€l[i] = IHSTab1e[ [i, 13]] , {i, 1, 200}] ;
Oo[€2[i] = IHSTab1e[ [i, 14]] , {i, 1, 200}] ;
Oo[Kl[i] = IHSTab1e[ [i, 15]] , {i, 1, 200}] ;
Do[K2[i] ;;; IHSTab1e[ [i, 16]] , {i, 1, 200}] ;
Do[Y1[i]

= IHSTab1e[ [i,

17)) , {i, 1, 200}] ;

Oo['n[i] = IHSTable[ [i, 18]] , {i, 1, 200}] ;
U:p%otect[V) ; V;;; 2.52.106 ;
c5[t~

:= 1/; t< 119.5

c5[t~

:'" -t + 120.5/ ; 119.55 t &&t < 120.5

c5 [t~ := 0/; 120.5 s t&& t < 239.5
c5[t_] := t- 239.5 /; 239.5 5 t&&t< 240.5
c5[t~

:;;; 1/; 240.55 t&&t< 359.5

c5[t_l := -t + 360.5 / ; 359.55 t&&t < 360.5
c5[t_] := 0/; 360.55 t
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odel = Yl '[t] == rss [i] *Yl [t] * (1.0 - (Yl[t] + Y2[t] + Y3[t] + Y4[t]) I (R[i]»
Fin[i] *0.8* Btotru.[i]

+

IV- Fin[i) *Yl[t) IV-al[i] *6[t] *Yl[t) -a2[i] * (1-6[t]) *Yl[t] +

Ih[i] * (1- 6 [t) *Y2 [t) + f32 [i) * 6 [t) *Y3 [t] - ~l [i] * 6 [t] *Ydt) - ~2[i] * (1- c5 [t]) *Y3 [t] ;

ode2 = Y2' [t] == rrs [i] *Y2 [t) * (1.0 - (Yl[t] + Y2[t) + Y3[t) + Ydt]) I (R[i)) +
Fin[i) * 0.09* Btotal[i]
f3l[i) * (1-6[t)

I V - Fin[i] *Y2[t] I V + al [i] * 6 [t] *Yl [t] - a2 [i) * (1- 6 [t]) *Y2[t) -

*Y2[t) +f32[i} *6[t] *Y4[t] -~2[i] * (1-6[t]) *Y2[t];

ode3 '" Y3' [t] == rsr [i] *Y3 [t] * (1.0 - (Yl[t] + Y2[t] + Y3[t] + y4[t]) I (R[i)) +
Fin[i] * 0.09* ~[i)

IV - Fin[i) *Y3[t) I V - al [i] * 6[t] *Y3 [t) + a2 [i] * (1- 6[t)) *Yl[t] +

,Bl[i) * (1-6[t]) *Y4[t) -f32[i) *c5[t) *Y3[t] -~l[i] *6[t] *Y3[t];

ode4= Y4' [t] == rn:-[i] *Ydt] * (1.0- (Yl[t] +Y2[t] +Y3[t] +Ydt]) I (R[i]» +
Fin[i] * 0.02* Btobu[i]

I V-

Fin[i] *Ydt] I V + Ql [i) * c5 [t] *Y3 [t) + a2 [i] * (1- 6 [t)) *Y2[t] -

,Bl[i] * (1- 6[t)) *Y4[t) -f32[i] *c5[t] *Y4[t];

odeS '" 1'5' [t] "'''' 12 * 800* (Yl[t] + Y3 [t)) * c5 [t) I (Kl [i) + Ydt) + Y3 [t)) -Yl [i) *1'5 [t] ;

ode6 = Y6' [t) "'= 12 * 13500* (Yl[t) + Y2 [t) * (1- c5 [t)) I (K2 [i] + Yl[t] + Y2[t)

-.2 [i) *Y6[t) ;

solutiontab1e =
Table[IDSolve[{odel, ode2, ode3, ode4, odeS, ode6, Yl[O] == 0.8*a[i)
Y2[O)

== 0.09*a[i)

I

Y3 [0)

I

== 0.09*a[i] , Y4 [0) == 0.02*a[i] ,1'5 [0) == 0, Y6[O) == O},

{Yl, Y2, Y3, Y4, 1'5, Y6}, {t, 0, 480}, MaxSteps-+ 10000000], {i, 1,200, 1});

finaloutccme[l] = Table[Yl[480) /. solutiontab1e[ [i)) I {i, 1, 2oo}] II Flatten
14
{5.50053x10 14 , 5.59588x10 14 , 7.15696x10 , 4.3064x10 14 , 4.17005x10 14 , 8.15753x10 14,
14
14
14
1
3.48684 x 10 , 4.13781 x 10 4, 6.71623x10 , 7.16351x10 14, 4.5463x10 , 5.74526x10 14 ,
14
14
14
14
14
3.66267x10 ,5.28508x10 ,6.78334x10 ,9.13357x10 , 4.27986x10 ,
14
14
14
14
14
7.95678x10 , 4.25739x10 , 2.07992 x 10 , 7.1967x10 , 4.38733x10 , 7.35277x10 14 ,
14
1.9042x10 14 , 6.47758x10 14 , 3.95808 x 10 14 , 1.65245x10 14 , 6.09172x10 , 7.67298x10 14 ,
U

U

U

D

U

U

7.0808x10 , 6.38678x10 ,6.53665x10 , 6.12261x10 ,5.90041x10 ,8.25347x10 ,
3.72487 X 10 14 , 7.28863 x 10 14 , 6.30466 x 10 14 , 3.40144 x 10 14 , 8.00207 x 10 14 , 3.42234 x 10 14 ,
14
5.31612 X 10 14 , 6.70176 x 10 , 2.59663 X 10 14 , 6.27128 X 10 14 , 1. 36092 x 10 14 , 5.55213 x 10 14 ,
5.83817x10 14 , 5.53829x10 14 , 3.06027 x 10 14 , 2.23083x10 14 , 1.43667x1014, 4.54995x10 14 ,
14
14
14
14
1.82373x 10 14 , 2.22235 x 10 , 1.1515 x 10 , 2.91332x 10 , 5.25x 10 , 9.85409x 10 14 ,
14
14
14
14
5.35757x10 , 6.18777x10 , 6.01427 x 10 , 5.09005x10 , 4.10351x10 14, 5.15843x10 14 ,
14
14
14
1
5.89758 x 10 14 , 1. 62071 x 10 , 4.58316 X 10 , 5.95425 X 10 , 2.31553 x 10 4, 8.88801 x 10 14 ,
14
14
14
14
5.47324 x 10 , 4.20226 X 10 , 1. 30787 x 10 , 7.28594 X 10 , 5.18844 x 10 14 , 8.38016 x 10 14 ,
14

14

14

14

14

14

14

U

U

14

14

14

6.33296x10 , 9.04889x10 ,7.84954x10 ,3.28639x10 ,4.84053x10 ,8.74729x10 ,
14
14
14
14
14
7.73112x10 14 , 3.50879x10 , 4.2257x10 , 8.32163x10 , 4.80703x10 , 4.89513x10 ,
14
14
14
14
14
14
6.44835x10 , 5.3406x10 , 3.22039x10 ,5.3888x10 , 4.42812x10 ,6.87621x10 ,
6.5212x10 14 , 4.75881x10 14 , 2.02964 x 10 14 , 8.12917x10 14, 1.94734x10 14 , 7.04113x10 14 ,
5.98293x10 , 4.35344x10 ,1.73288x10 ,2.97472x10 ,4.99322x10 ,2.13828x10 ,
14
5.03811x10 14 , 3.88899x10 , 2.66682 x 10 14 , 4.94735x10 14 , 4.72336x10 14 , 3.75855x10 14 ,
14
7 .90459x 10 , 3.82761 x 10 14 , 3.80677 x 10 14 , 9.25709x 101~, 5.03977 x 10 14 , 8.02264 x lOB,
14
14
14
3.55455x10 14 , 2.39956x10 , 7.60826x10 , 6.62994x10 14 , 5.81652x10 ,
14
14
14
14
2.71427x10 , 3.69424x10 , 5.19328x10 , 6.05967x10 , 4.0798x1014, 7.56154x10 14,
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14
14
14
14
14
14
5.42772x10 ,3.87513x10 ,4.03753x10 ,4.9324x10 ,4.76723x10 ,2.80497x10 ,
3.32405x10 14 , 6.89312 x 10 14 , 4.8814 x 10 14, 4.45353x10 14, 3.18004x10 14 , 2.76115x10 14 ,
6.4154x10 14 ,6.18401x10 14 ,4.65522x10 14 ,3.35362x10 14 ,3.59876x10 14 ,8.5990lx10 14 ,
2.34852x10 14 , 3.19592x10 14 , 7.48889 x 10 14 ,
8.67065x10 14, 5.12822x10 14 , 5.67654x10 14 ,
4.62553 X 10 14 , 6.96885 x 10 14, 6.22999 X 10 14 ,
2.83308x10 14 , 2.86543x10 14 , 6.83754 x 10 14 ,

5.62684x10 14 , 4.98853x10 14 , 5.97748x10 14 ,
4.00575x10 14, 5.76394x10 14 , 4.3616x10 14 ,
5.22789 X 10 14 , 7.00567 X 10 14 , 3.08703 x 10 14,

1.04249x10 14 , 5.09799x10 14 , 7.81381x10 14 ,
14
14
14
2.44667 x 10 , 7.38504 x 10 , 3. 91334 x 10 , 4.14099 x 1013, 1. 54353 x 10 14, 2.99933 x 10 14 ,
6.590l3x10 14 , 7.49296x10 14 , 8.46975 x 10 14 , 5.74529x10 14, 4.49627x10 14,
3.99963x10 14 , 2.49516x10 14 , 4.69938x10 14 , 3.6391x 10 14 , 6.11938x 10 14 , 5.63661x10 14 ,
5.69265x10 14 ,5.43594x10 14 ,4.81762x10 14 ,3.45765x10 14 ,6.77045x10 14 ,
4.62251x10 14 ,2.57342x10 14 ,9.86302x10 13 ,3.12828x10 14 ,4.49498x10 14 ,6.6451x10 14 }

Di..spersi.CXlReport[£inaloutoc:me [1] ]
{Variance --7 4.121 x 1028 , StandardDeviation --7 2.03002 x 10 14 ,
Samp1eRange --7 9.43999 X 10 14 , MeanDeviation --7 1.65303 x 10 14 ,
MedianDeviation --7 1.46978 x 10 14 , QuartileDeviation --71.46703 x 1014}

Min [£inaloutoc:me [1] ]
4 .14099x 1013
Max [ finaloutoc:me [1] ]

9.85409x 10 14

Mean[£inaloutoc:me[l] ]
4.96501 x 10 14
£inaloutoc:me[2] = Tab1e[Y2[480] /. soluti.cntable[ [i]], {i, I, 200}] / / Flatten
{134729., 2l3515., 230276., 178944., 148268., 33641.2,256706.,199911.,85994.2,154129.,
194791.,116074.,197299.,60846.3,82592.7, 9l378.3, 82469.2,240612.,214952.,
154710.,190974.,66020.8,154443.,93244.8, 76239.3,253652.,96966.1,73166.7,
149118., 64850.9, 25313.3, 128511., 184212., 155824., 153902., 141186., l36316.,
92090.8,148619.,114605.,123418.,170531.,85751.3, 250260.,83441.,144470.,190399.,
250775.,162909.,215940.,210426.,223272., 130639.,120955.,126445.,177456.,
118469.,145732.,48254.,199285.,118426.,161740., 246782.,201983.,48409.9,
142720.,148812.,238305.,154806.,23483.1, 164346.,143114.,130383.,168739.,
150202.,276477.,93618.5,174888.,104087., 178127.,163852.,143007.,113925.,
75592.2,61261.5,153824., 63759.6, 46469.8, 110791., 166864., 97264.6, 149994.,
178251.,83590.5,140239.,108073.,243333.,130331., 125584.,196247.,126286.,
155174.,12603.1, 18l306., 270885., 138341., 47276.1,116795.,178998.,278190.,
247596.,150674.,266804.,125022.,162225., 214366.,103849.,69294.2,121553.,
180189.,164333.,217585.,99932.7, 17l426., 66973.4,50044.1,188683.,78884.9,
126135.,225877.,195839.,82218.2,95034.6, 166948.,152229.,185924.,139631.,
254965.,88860.1,100259.,148526.,98174.3, 29878.4,81536.1,48477.1,214047.,
159161.,161092.,145900.,275688.,64213.3,219462., 170163.,111826.,83641.5,
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103402.,271911.,146984.,67347.9,201383.,39371.9, 190664.,130736.,235405.,
134648.,214568.,115859.,217334.,124534.,231625., 107730.,147608.,164201.,
134206.,159219.,118053.,117931.,280810.,151054., 205758.,215613.,13338.9,
115291.,233286.,223429.,138397.,65240.7, 168507.,200794.,144650.,87288.,
152459.,152390.,129721.,188001.,148479.,291951., 74342.1,184295.,111262.)

Dispers:i.onRepo[fina.l.out:oc:ue [2] ]
{Variance~ 3.74766xl0 9 , StandardDeviation~ 61218.2, SampleRange~ 279348.,
MeanDeviation ~ 48687.6, MedianDeviation ~ 42593.3, QuartileDeviation ~ 42358.3}
Min [fina1out:oc:ue [2] ]

12603.1

Max[finalout:oc:ue[2] ]
291951.

Mean[finaloutoame[2]]
147168.
finaloutcxme[3] = Table [Y3 [ 480] I. solutiontabJ.e[ [i]], {i, 1, 200}] /I Flatten
r
,2.26559xl0 10 , 1.64634xl0 10 , 2.0052xl0 10 , 1.4082xl010 , 1.0457xl0 10 , 1. 17063x 10 10 ,
9
10
7.664xl0,1.50105xl0
,1.54466xl0 10 , 1.43269xl010 , 1.28353xl0 10 ,1.88607x10 10 ,
9
9.45245xl0,
1.29438xl0 10 , 1.9514x10 10 , 2.63703xl0 10 , 1.0305xl0 10 ,2.96109x10 10 ,
9
7.67436 x 10 , 4.70097 x 10 9 , 1.01319 x 1010, 1.4878 x 10 10 , 1.57539 x 10 10 , 3.80977 x 10 9 ,
9
9
2.40861><10 10 , 1.28644x10 10 , 4.01399xl0,
6.54963xl0,
1.7186x10 10 ,2.35406xl0 10 ,
10
9
9
10
2.50834xl0 , 9.17995xl0, 2.0478xl0, 1.76665xl0 , 5.55608x10 10 ,6.38529xl0 10 ,
9
9
2.0009xl0 10 , 4.55657xl0 9 , 5.77666xl0,
1.67649x 10 10 , 3.03853x 10,
9.89338xlO 9 ,
10
9
10
9
10
1.64l97xlO , 7.4689lxlO, 2.76626xl0 , 7.24047xl0, 1.2282 x 10 ,1.7975xl0 10 ,
1.84025x 10 10 , 2.8432 x 10 9 , 3.85072 x 10 9, 4.91776x 10 9 , 6.25738x 10 9, 5.33367x 10 9 ,
9
9
9
9
3.39728xlO,
1.l8013x10,
6.35388x10,
1.45926xlO 10 , 1.94426xlO 10 , 9.3l72xl0,
1. 66926 x 1010, 9.52058 x 10 9 , 2.682 x 1010, 2.06138 x 1010, 1. 24 926 x 10 10 , 1. 5922 x 1010,
9
9
9
1.71736xlO,
1.81394x10 10 , 1.8l934xlO10 , 5.9l44xlO,
1.5l002xlO10 , 5.14l61xl0,
4.52726xl0 9 , 2.l9076xl0 9 , 9.20365xl0 9 , 2.50559x 10 9 , 1.09147x 1010, 1.22399xlOl0,
3.40131x10 10 , 4.52826xl0 9 , 7.36786xl0 9, 2.9684lxl0 1O , 2.70207x10 10 , 2.33597xlO W ,
9
9
9
9.29984x10,
1.50272xlO 10 , 6.81547xlO,
4.85879xlO,
1.60902x10 10 ,l.l4432xlO 10 ,

9
91010
1.l263lx10 10 , 6.58322xlO,
1.14978xlO 10 , 5.42l28xlO,
1.97959xlO ,1.83255xlO ,
9
9
10
9
9
7.45745xlO, 4.81822xlO, 3.l7555x10 , 3.76574xl0, 1.97066xlO 10 , 6.54745xlO,

1.2858xl010, 6.24058xl0 9 , 6.l6682xl0 9 , 1.36374 x 1010, 2.90928xl0 9 , 8.66542xl0 9 ,
9
9
9
9
8.39336xl0,
5.20671xlO,
5.24967xl0,
1.06429x10 10 , 8.550l5xlO,
1.11324 x 10 10 ,
l.l7406xlO 10 , 1.02585xlO 10 , 2.02928xl0 10 , 1.1l663xl0 10 , 1.59821 x 10 9,
9
9
9
7.30849xlO,
6.04876xlO,
5.03035.xlO 10 , 5.35173x 10,
2.46833x 10 10 , 5.73448xl0 9 ,
9
10
10
9
9
5.46227xl0, 1.22007x10 , 1.30057x10 , 7.20972xlO, 1.87193xlO 10 , 7.01399x10,
9
9
1.43338xlO 10 , 5.00436xl0,
2.62901 xl0 10 , 2.84429x 10 10 , 8.552x 10,
7.16429xl0 9 ,

2.87873 x 1010, 1. 67299 x 1010, 9.66717 x 10 9 , 9.93059 x 10 9 , 7.06989 x 10 9 , 2.40542 x 1010,
9

10

10

91010

1.68072x10 , 4.25695xl0, 1.64736xl0 , 7.57549x10, 1.79308x10 ,2.42491xl0
1. 88891 x 10

10

,

2.69111 x 1010, 1. 61623 x 1010, 1. 31225 x 10 10 , 4.51919 x 1010,
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,

1.67984xl0 1O , 7.63062xl0 9, 1.26611 x 10 10 , 8,55538xl0 9, 1.95216x10 l0 , 8.59597x10 9,
2.59851xl0 1O , 2.41891x10 l0 , 9.79205xl0 9, 1.70948x10 1O , 1.21317 x 10 10 ,
8.63055x10 9, 1.92768 x 10 9, 5.84007x10 9, 5.35043x 10 9, 1.82177 x 10 9, 1.23517 x 1010,
3.13505x10 1O , 4.17692x10 9, 1.00121 x 1010, 6.10346x10 9, 2.74216x10 9 , 6.71412x10 9 ,
1..19106 x 1010, 1. 41089 x 1010, 2.42659 x 1010 , 2.31624 x 1010, 1. 65293 x 1010,
1. 28581 x 1010, 4.30904 x 1010, 1. 68643 x 10 10 , 1. 91113 x 1010, 9.29937 x 10 9, 9.99234 x 10 9,
1. 58248 x 1010, 7.90921 x 10 9, 1. 95818 x 10 9, 5.83029 x 10 9, 6.05545 x 10 9, 1. 2075 x 1010,
2.1645 x 10 10 , 4.50611 x 10 9, 1. 96731 x 10 9 , 5.28604 x 10 9, 1. 25041 x 10 10 , 7.02217 x 109}

Dispersic.aP.eport[ finaloutoare [3] ]
{Variance ~ 9.38132 x 10 19 , StandardDeviation ~ 9.68572 x 10 9,
SampleRange ~ 6.29185 x 1010, MeanDeviation ~ 7.1197 x 10 9,
MedianDeviation ~ 5.42527 x 109, QuartileDeviation ~ 5.74653 x 109}
Min [final.outccme [3] ]
1.18013 x 109
Max [final.outccme[ 3] ]

6.40986 x 1010

M:Ian[finaloutocme[3] ]
1. 33624 x 1010

finaloutccme[4]:: Table[Y4[480) /. solutiontable[[i]], {i, 1, 200}) 1/ Flatten
6 7 6 6
{2.91357xl0,
1.81494x10, 954501.,304486., 2.77112xlO, 230913., 376932., 4.63282x10,
7
111234.,478562.,393360.,292705., 3.08387x10 6, 356872., 203280., 2.42908x10 ,
124222., 1.17581xl07 , 331125.,486830.,308884., 2.34734x10 6 , 283950., 160433.,
867326., 1.17491x10 6, 145003.,455334., 1.80598x10 6 , 1.30l46x10 6 , 8.004l4x10 6 ,
311501., 1. 62271 x 10 6, 658783., 1.38251 x 10 7 , 1. 92631 x lOll, 1.15565 x 10 6 , 157370.,

.

1.08693xl0 7 , 5.59774xl0 6, 1.59846x10 6, 790526., 1.59926xl0 6 , 766050., 3.15921xl0
6

6

7

,

8

1. 74592 x 10 , 419684., 3.02161 x 10 , 890424., 364931., 1. 39639 x 10 , 372039., 665683.,
8.17632x10 6, 3.38029x10 6, 310353., 2.69313x10 6 , 1.97623xl0 6 , 578365.,268689.,
7
7 6 7
1.47967x10,
237600.,796051., 1.57859x10,
3.27551x10, 1.04386x10, 223532.,

1. 50187 x 10 6 , 1.14146 x 10 6 , 285351., 479508., 322571., 223866., 326503., 952523.,
549197., 212667., 3.84563 x 10 6 , 5.45904 x 10 8 , 669315., 498659., 1. 85392 x 10 6 ,
9.51603x10 8 , 2.79154xl0 6, 484238., 1.9396x10 7 , 85095.8,61245.4,338153.,
6
324326., 1.686l4xlO,
214495.,740411., 4.055lxl0 6 ,1.20057x10 6 ,1.28906xl0 6 ,

6
384527.,180713., 1.89466x10 6 ,335721.,225113.,651032., 8.48039x10,
487877.,

1.80457x10 6, 3.03925xl0 6 , 122680., 1.25401x10 6 , 276625.,360845.,474643.,
304128., 515820., 184264., 1. 92708 x 10 7 , 280922., 176731., 133591., 179780.,
534923., 9.96093x10 9, 6.37336x10 10 , 1.81206x10 1O , 4.0873x10 6 , 151849.,93385.1,
1.06453 x 10 6, 311267., 8.16715 x 10 9, 389690., 1.01564 x 10 6 , 5.77232 x 10 10 , 130303.,
7.07124x10 6, 6.97619xl0 7 , 342879.,924301.,501575.,261136.,163145., 3.09752x 10 6 ,
2.07063xl0 6 , 2.86134xl0 9 , 792288.,93679.9, 4.78279x10 6 , 259469., 8.99844x10 6 ,
8

7

6

7

5.94641xlO, 1.26439xlO, 315679., 4.84296xlO, 286665., 2.60537x10, 172923.,
166955.,710447., 3.47536x10 6 , 285897., 1.05568xl0 6 , 4.32758xl0 8 , 3.01484xl0 6 ,
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182150., 1.47717x10 6, 191446., 2.83417x10 7 , 269928., 314331., 235861., 532555.,
7
7
6
7.53978x10,
1.28103x10,
491949.,181,585.,190793.,331555., 1.48737x10,
676512.,
6
6
7
6
7l4411., 7.24329x10, 578631., 7.88469x10, 371738., 6.69365x10, 3.56316x10,

7 6 8
2.29532x10,
5.14928x10, 535175.,316840., 1.19636x10 ,578914.,373618.,
782934.,704079.,376082., 1.2221x10 6 , 394411., 5.46545x10 6 , 4.80723x10 6, 243736.)
~[fina1out:cxme[4]

]
{Variance ~ 3.18424 x 1020, StandardDeviation ~ 1. 78444 x 10 10 , SampleRange ~ 2.03706 x lOll,
MeanDeviation ~ 4.50843 X 10 9 , MedianDeviation ~ 530562., QuartileDeviation ~ 1.69679 x 106}

Min [finalout:cxme[ 4] ]
61245.4
Max [fina1out:cxme[ 4] ]

2.03707 x lOll
Maan [finalout:cxme [4] ]

2.35697 x 10 9

finalout:cxme[5] = Table[Ys[480] I. solutiontable[[i]], {i, 1, 200}] II Flatten;
Chq:>[finalout:cxme[5] ]
{ 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0,

0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,

0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0,

0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,

0, 0, 0, 0,
0, 0, 0, 0,
0, 0, 0, 0,
0, 0, 0, O}

fina1out:cxme[6] = Table[Y6[480] I. solutiontable[ [i]] , {i, 1, 200}] I I Flatten
:9695.89,9853.78,8894.89,10808.6,10124.5, 9028.92,12195.5,10097.7,9639.27,10495.8,
10270.1,11518.4,10439.3,9371.11,9017.06,10607.6, 11687.,10634.9,10045.5,
9904.26,9178.45,11114.6,8635.53,9866.43,9719.25, 9983.07,9099.43,10326.9,
10149.1,9659.27,10858.8,9799.85,10177.1,10013., 10381.9,9451.38,8787.64,
8740.07,11587.6,11088.7,9743.85,10028.9,9843.1, 10089.2,9556.16,11162.4,
9721.93,11302.5,10254.7,10565.7,8983.52,9758.86, 11402.8,9229.05,10245.4,
10523.2, 11802.2, 10110.5, 11322.3, 11723.9, 10671., 12298.4,9665.69,10293.8,
8677.92,9134.79,8558.56,10446.7,10976.5,9877.58, 9483.,10165.,9572.18,9414.55,
10823.4,9427.14,9383.53,9544.,9465.15, 9150.91,10364.6,10685.6,10281.6,
9293.18,10301.9, 9949.64, 10039., 10699.1, 11150.2, 9589.21,11881.1,9261.86,
10204.8,9088.58,10795.,11085.7,10122.,10761.5, 8868.46,10471.3,11272.6,
9680.48,11472.5,10428.3,8784.21,9787.03, 10959.8,10317.9,9516.82,11826.3,
9520.77,12004.7,9707.9,10918.7,9198.35, 9622.57,10189.9,9970.92,9308.39,
8931.56, 11639.6, 9834.1, 10004.8, 9899.24, 9993.35, 9064.8, 9477.43, 9121. 79,
11212.5,9597.25,9776.68,9566.13,9442.89,10867.7, 10219.6,10377.2,8890.61,
10934.,10737.4,10404.5,11462.1,9957.23,9941.42, 11190.5,10659.1,10135.5,
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10075.8,11341.8,10060.,9823.71,8941.9,10023.9, 10590.7,9606.68,9054.33,
9287.97,10065.1,11248.1,10349.8,11949.3, 8839.58,9505.93,9335.7,10339.4,
10235.7,9649.39,9237.3,11399.9,9201.34,10402.4, 10515.9,8996.88,11050.8,
9329.64,10551.5,9916.75,11027.3,9734.87,11538.3, 10467.9,10986.9,8720.21,
9260.88,11014.7,10722.5,9816.42,10846.1, 10638.9,9774.69,10605.1,10895.9,
10174.4,10490.9,9890.23,9931.69,10767.6, 10539.6,10209.9,9351.82, 9401.13}
DispersicmReport[ final.outccme[ 6] ]
{Variance~ 664000., StandardDeviation~ 814.862,

SarnpleRange~

3739.84,

MeanDeviation ~ 660.713, MedianDeviation ~ 566.473, QuartileDeviation ~ 572. 968}
Min [finaloutccme [6] ]

8558.56
Max [final.outoc:me [6} ]

12298.4
l>&m[finaloutccme[6} }
10139.
Do[rankoolum[j]

= Tabl.e[Position[sanpJ.edval.ues[j]

, lhsc:olum[j] [[i]}} , {i, 1, 200}] /1

Flatten, {j, 1, IS}]
rankoolumfunctian[n_,

k~

:= rankoolum[k] [[n]]

rankmatrix = Array[rankcolumfunct:ion, {200, IS}] ;

ordel:edfinal.outccme[l]
rankoolurn[19] =

= Sort[finaloutoc:me[l]] ;

Tabl.e[Position[oJ:deI:edfi.naloutoc:me[l] , final.outocme[l} [[iJ]] , {i, 1, 200}} II Flatten;
rankmatrixBss = Array[rankoolumfunct:ion, {200, 19}] ;

'lBss = Transpose [ranJanatri.xBss] ;

Do[ c[i, j] =

'~('lBss[ [i,

lbl

tJ] - 201/2) * ('lBss[ [j, tJ] - 201/2»)

~-(~ ('lBss[[i, tJ] ~ 201/2) 2) *

(I

('lBss [[j, s]] - 201/2)

1

2) , {i,

1, IS},

{j, 1, IS}]

Do[c[i, 19]

= 'l:(Tass[[i,

lbl

t]]-201/2)

* ('lBss[[19,

t]) -201/2»)1

-v' H~ (Tass [[i, tJ] - 201 /2) 2) * (~ ('lBss [[19, s]) - 20112) 2)), {i, 1, IS}]
Do[c[19, i] = c[i, 19] , {i, 1, IS}}
c[19, 19} = 1;
Ur.protect[C] ; Cl. = Array[c, {19, 19}] ;
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B1 = Inverse [elll N] ;
Do[-rBss[i) = -B1[[i, 19)) /

y B1[ [i, i)) * B1[ [19,

19)) II N, {i, 1, 14}]

PAXinpu~

= Table[~ [i), {i, 1, 14})
{-0.0776149, 0.999989, -0.0656751,0.0984684, 0.00416987, -0.0728436, 0.0555663,
-0.319124, 0.03044l3, 0.0736761, -0.0819341, 0.103606, -0.0282147, -0.0160582}

Do[tBss[iJ=~[iJ* "VI 1- yBss [1)
~98*¥Bss[1]
_

IIN,{i,1,14}]

tstatistic.sBss = Table[tBss [i) , {i, 1, 14} J
{-1.09544, 2939.79, -0.926l3, 1.39234,0.0586758, -1.02773, 0.783097,
-4.73822,0.428546,1.03954, -1.15681,1.46576, -0.397l73, -0.225988}

Do[siqlevell[i) = 2- 2*CDF[SbJden1::mistributicn[198] , Sign[tBss[iJ) *tBss[i)),
{i, 1, 14}}
si.gnifi~

= Table[sig1eve11[i} , {i, 1, 14} J
{0.274654, 2.485700857820xl0- 461 , 0.355506,0.165381,0.95327,0.305331,0.434506,
4.10863xl0- 6 , 0.668719,0.299821,0.248746,0.144301,0.691667, 0.821444}

~inaloutoc:me[2)

= Sort[finaloutoc:me[2] J;

rankool.um[19] =
Table[Positicn[~inaloutoc:me[2} , finaloutccme[2} [[i)) J , {i, 1, 200} J II Flatten;
ranJcmatrixBrs = Array [rankool.umfuncti.cn, {200, 19}] ;

mrs = Transpose [ranJcmatrixBrsJ ;

Do[c2[i, j} =

{2:

(mrs [ [i, tJ) - 201/2) * {mrs [ [j, t]} - 201/2») /

t=1

~ (r ('lBxs[[i, t]] ~;~1/2)2) * (r (mrs[[j, sJ) -201/2)2)
{j, 1, 18}]
Do[c2[i, 19] =

, {i, 1, 18},

~1

t=1

{f

(mrs [ [i, tJ] - 201/2) * ('lBxs[ [19, t)) - 201/2») /

t=1

-V {{~ (mrs[[i, t]] -201/2)2) * {~(mrs[ [19, s)) - 201/2)2)), {i, 1, 18}]
Do[c2[19, i) = c2[i, 19], {i, 1, 18}}
c2[19, 19) = 1;
Unprotect[C] ; C2 =Array[c2, {19, 19}) ;

B2 = Inverse[C211 N] ;
Do[-.Brs[i) = -B2[ [i, 19}) /
m::x:inpu~

.y B2[[i, i)) * B2[ [19, 19))

/I N, {i, 1, 14}]

= Table[-.Brs [i} , {i, 1, 14})

{0.00978377, 0.111723, 0.986615, -0.158037, 0.168761, -0.0427989, -0.0835763,
0.8786, -0.0692339, 0.0598107, -0.0593243, 0.0090944, -0.00995819, -0.104315}

59

Oo[~[i]

r-- .

~98

.
/I N, {i, I, 14l]
1- yBrs [~] *YBrs[~]
tstatisticsBrs = Table[~ [i), {i, I, 14}]
{0.137676, 1.58199, 85.1375, -2.25208, 2.40923, -0.602786, -1.18015,
=¥Bm[i] *

\j

25.8879, -0.976551, 0.843121, -0.83624, 0.127975, -0.140131, -1.47589}
Oo[siq1evel2[i] = 2- 2*CDF[Sbldent'lDistril::uticn[198],

Sign[~[i]]

* ~ [i]],

{i, I, 14}]
significance.l.evel.sPR:CSanCB.rs = Tabl.e[siqJ.evel2[i], {i, I, 14}]
{0.890636, 0.115248, 0., 0.0254148, 0.0169018, 0.547341,

0.239356,0.,0.329983,0.400178,0.404028, 0.898299, 0.888699, 0.141561}
oxderedfinalout.ocme[3] = Sort[fina1out.oc:ae[3]] ;
rankcolum[19] =
Tabl.e[Positi.cm[ordel:edfina1out.oc:ae[3] , fina1out.oc:ae[3] [[ill] , {i, I, 200}] /I Flatten;
rankmatrixBsr = Al:ray[rankco1.umfuncti.cm, {200, 19}] ;
'l'Bsr = Transpose [rankmatrixBsr] ;

Oo[ c3[i, j] =

{I:

('l'Bsr[ [i, t]] - 201/2) * ('l'Bsr[ [j, t]] - 201/ 2 )}

1:=1

I

,----~~~~~~~~~~~~~-------------

(!

('lBsr[ [i, t]] - 201/2)

{j, I, 18}]
Oo[c3[i, 19] =

2) * (! ('l'Bsr [[j, s]] - 201/2) 2) , {i,

I, 18},

~l

t:=l

(I:

('lBsr[[i, t]] -201/2) * ('lBsr[[19, t]] -201/2)}1

t:=l

,d{~('l'Bsr[[i, t]] -201/2)2}*(~('l'Bsr[[19, s]] -201/2)2)},

{i, 1, 19}]

00[c3[19, i) = c3[i, 19] , {i, I, 19}]
c3[19, 19] = 1;
Ur:protect[C] ; C3 = Al:ray[c3, {19, 19}];

B3 = InveJ:se[C3 liN] ;
Oo[¥Bsr[i] = -B3[ [i, 19]]

/.y B3[

[i, i]] * B3[ [19, 19]] /I N, {i, I, 14}]

PR:X:iJ:pltpararnsandBsr = Tabl.e [¥Bsr [ i) , {i, I, 14}]
{0.0359044, 0.872152, 0.078262, -0.637174, -0.0144595, 0.623413, 0.0626986,
-0.521915,0.0302684, 0.861561,0.0081576, -0.0734403, -0.036471, 0.0749015}

~

198
.

.
/I N, {i, I, 14}]
1- ¥Bsr [~] * YBm-[~]
tstatisticsBsr=Table[tBsr[i], {i, I, 14}]
{0.505545, 25.0846, 1.10463, -11.6331, -0.203484, 11.2192, 0.883986,

Oo[tBsr[i] =YBsr[i] *

-8.60963,0.426109, 23.8809,0.114791, -1.0362, -0.513534, 1.05693}
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Do [siglevel.3 [i] = 2 - 2 * CDF[ SbJdent'lDistriblticn [198], Sign [ tBsr[ ill * tBsr [ill ,

{i, 1, 14}]
significanoel.evelsPRXSandBsr = Tab1e[sig1evel..3[i], {i, 1, 14}]
{0.613738, 0., 0.27066, 0., 0.838966, 0., 0.377776,
2.22045x10-15, 0.670491,0.,0.908727,0.301375,0.608151, 0.291833}
OJ:dered:final.ollt:cane[4]
rank001mn[19] =

= Sort[finalout:cane[4]];

Tab1e[Positicn[on:lenadfinaloutocme[4] , finaloutcxme[4] [[i]]] , {i, 1, 200}] /I Flatten;

ranJcmatrixBn- = Ax1'ay[rankcol:amfuncticn, {200, 19}] ;
~

= Transp:>se [rankmatrixB.tr] ;

Do[ c4[i, j] =

{~ ('1B.rr[ [i,

t]] - 201/2)

* ('1B.rr[ [j,

t]] - 201/2»)

&1

('1B.rr[[i,
{~
t,,1

tl1 -201/2)2) * {~('1B.rr[[j,
~1

1

s]] -201/2)2) , {i, 1, 18},

{j, 1, 18}]

Do[c4[i, 19] =

(l:(~[[i'

t]] -201/2)

*

t,,1

"J' H~ ('lBa

[[i, t]] - 201/2)

(~[[19, t]] -201/2»)1

2) * {~ ('1B.rr [[19, s]] - 201/2) 2)), {i, 1, 19}]

Do[c4[19, i] = c[i, 19], {i, 1, 18}]
c4[19, 19] = 1;
UI:protect[ C] ; C4 ;;: Ax1'ay [ c4, {19, 19}] ;

B4 = Inverse[C4 lIN] ;

Do[~[i] = -B4[ [i, 19]]

/.y B4[ [i, i]] * B4[ [19, 19]J

/I N, {i, 1, 14}]

PRX:il:pl~=Tab1e[~[i],

{i, 1, 14}]
{0.00839003, 0.110428, 0.166616, -0.418732, -0.0184253, -0.0129835, 0.409715,
-0.688149,0.033012, 0.121917,0.00430189,0.00198342, -0.00585949, 0.0393947}

Do[tB.rr[i]=~[i]* I

'J

~98

.

1- ¥B.c: [1] * yB.rr[1]
tstatisticsB.rr = Tab1e[tBrr [i], {i, 1, 14}]

IIN,{i,1,14>]

{0.118062, 1.56343,2.37773, -6.4883, -0.259311, -0.182709,6.32001,
-13.3455,0.464773,1.72842,0.0605335,0.0279093, -0.0824517, 0.554764}
Do[sig1evel4[i] = 2- 2*CDF[Student'lDistriblticn[198], Sign[tBrr[i]] * tBrr[i]] ,
{i, 1, 14}]
significancelevels~

= Tab1e[siql.evel.4[i] , {i, 1, 14}]
{0.906138, 0.119549, 0.0183716, 6.80493x10- 10 , 0.795665, 0.855213,

1.69641x10- 9 , 0.,0.642604,0.085471,0.951792,0.977763,0.934371, 0.579682}
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APPENDIX 2
Calculation of Partial Rank Correlation Coefficients

The following technique, adapted from [9], is used to calculate PRee's between input
variables and a single output variable. The process is repeated separately for each output
variable.

Add outcome vector to the NxK LHS table as column K+l. Form a new Nx(K+l)
matrix by replacing each value in the original matrix by its rank. For each column, assign
the smallest value in the column a rank of 1, the next largest value a rank of 2, continuing
in this fashion until the largest value in the column is assigned a rank of N. If two
parameters have identical ranks on every run of the model, then use only one of those
parameters in calculating PRee's. The new matrix has the form

where

rs/ =

rJ)

r2)

rJ2

Y22

rJN

Y2N

rKN

RN

rank of s'h input parameter on t'h run of model and R,

=

rank of outcome

variable on t'h run of model (s = 1,2, ... ,K; t = 1,2, ... ,N).
Define the (K+ l)x(K+ 1) symmetric correlation matrix e, with elements cU', as follows:

f(ril _1+ N)(rjt _1+ N)
2

1=1

Cij

=

2

--;====================
N

L
1=1

l+N 2(
L
(rit--2 )
N

s=1

62

l+N
2

Tjs---

)2

For the

Ci,K+i

elements of C, replace

rjt

and

rjs

with R i • Elements on the main diagonal of

C are all ones. The formula above is Pearson's product moment correlation coefficient
(See Conover [64], p. 244). A discussion of the correlation matrix is included in Kendall
& Stuart [65], pp. 338-339.

Let B

= (h ij ) = C 1•

of the

th

'}{. K + 1 =

The outcome variable may be viewed as parameter K+ 1. The PRCC

parameter with respect to the outcome variable is Yi.K+I:

- (cofactor of C;,K + 1)

(Kendall & Stuart [65],

----r='=============
~(cofactor of cii)(cofactor of Ci,K + 1)

pp. 339-340)

- (cofactor of Ci,K + 1)
detC
(

(cofactor of Ci; ))( (cofactor of Ci,K +
detC
detC

1))

-hi.K + 1

Significance of nonzero PRCC's are determined with the statistic

t;, K + 1

= ]f, K + 1

where the variable t

(Blower & Dowlatabadi [9])

IS

distributed

III

Student's t-distribution with N - 2 degrees of

freedom.
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